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resumo 
 
 
O presente relatório descreve as atividades desenvolvidas e a experiência 
adquirida durante o estágio curricular realizado na DATAMEDICA, Serviços e 
Consultoria em Bioestatística, Lda., no âmbito do Mestrado em Biomedicina 
Farmacêutica. 
 
O estágio, que decorreu de Setembro de 2014 a Abril de 2015, permitiu a 
realização de diversas atividades relacionadas com Investigação Clínica, das 
quais se destacam: preparação de submissões de estudos clínicos às 
Autoridades Competentes; monitorização; medical writing e data management. 
 
Todo o trabalho desenvolvido durante este estágio foi fundamental para a 
aquisição de novas competências e desenvolvimento de antigas, tais como 
comunicação, concentração, sentido de responsabilidade, organização e 
resposta em situações de stress, que contribuíram para uma melhor 
preparação a nível profissional, pessoal e social face à Investigação Clínica e 
seus principais stakeholders. Adicionalmente, o estágio permitiu contactar com 
as atividades do quotidiano de uma Clinical Research Organisation (CRO) Full 
Service e colocar em prática os conhecimentos adquiridos durante a formação 
na Universidade. 
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abstract 
 
The present report outlines the activities developed and the acquired 
experience during the curricular internship at DATAMEDICA, Serviços e 
Consultoria em Bioestatística, Lda., under the scope of the Pharmaceutical 
Biomedicine Master Course. 
 
The internship, which took place between September 2014 and April 2015, 
allowed the performance of several activities related to Clinical Research, 
namely preparation of clinical studies submissions to Competent Authorities; 
monitoring activities; medical writing and data management. 
 
The work developed during this internship was essential both to acquire an 
important basis regarding new professional, personal and social skills and to 
develop old ones face to Clinical Research and its most relevant stakeholders, 
such as communication, concentration, sense of responsibility, organisation 
and correct response in stressful situations. The internship also allowed me to 
contact with the daily life activities of a Full Service Clinical Research 
Organisation (CRO) and put into practice the knowledge acquired at the 
University. 
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1. INTRODUCTION 
The present work consists on a curricular internship report developed under the scope of the 
Pharmaceutical Medicine Master Course at the University of Aveiro. Due to my desire to start the 
internship earlier, I started to work as a trainee at DATAMEDICA on June 2014. However, the 
curricular internship only took place between September 2014 and April 2015 at DATAMEDICA, 
Serviços e Consultoria em Bioestatística, Lda., and, therefore, this report will only mention the 
activities performed during that period. 
During the internship period I held a Clinical Research Associate (CRA) Trainee position. However, 
the internship also intended to provide me with a much broader perspective of the working 
environment and to introduce me to all the Company’s projects. Thus, I executed several activities 
beyond CRA position, such as medical writing, pharmacoeconomic studies, data management and 
quality assurance (QA). 
This report describes my experience as a trainee at DATAMEDICA and addresses the internship 
objectives, discussing the challenges, skills and knowledge acquired.  
The selection of DATAMEDICA as the host company of my internship was advised by my Master’s 
Professors. Besides their opinion, it was also my intention to conduct the internship at a CRO 
because I wanted to obtain knowledge and experience in other fields than clinical studies 
monitoring. Due to my willingness to learn and work, it was given to me the opportunity to start 
performing activities before the period of the curricular internship. 
This report presents the activities developed during the internship at the Host Institution, as well as 
all the learning outcomes and skills acquired during this training period. In general terms, this report 
will address the structure and operating procedures of the Host Company and the current state of 
the art in Clinical Research, namely applied legislation, regulatory authorities and, finally, a little 
glimpse about Portuguese and European Clinical Trials framework. A brief introduction to each 
theme and training area mentioned above will be given, the most relevant activities performed will 
be described, and the way these activities were performed will be explained. A discussion of the 
relevant aspects of this training period, detailing the problems and challenges faced and all the 
positive aspects identified will help to understand how the proposed learning objectives were 
achieved. Also, the conclusions taken from this period and the impact of these seven-months on 
personal and professional growth will be presented.  
2 
1.1 Internship Objectives 
The main objective of this internship was to attain new knowledge and competences in Clinical 
Research, since the conception, submission and implementation of clinical studies, to the critical 
interpretation of data and publication of studies’ results. The development and achievement of the 
main objective was initially proposed to be attempted by the following tasks: 
 Collect practical knowledge about the operating procedures of Clinical Research and 
related responsibilities; 
 Apply and consolidate the theoretical knowledge acquired at the Pharmaceutical Medicine 
Master Course and at Biomedical Sciences Degree; 
 Establish professional contacts through the collaboration with other Clinical Research 
professionals; 
 Develop important teamwork skills and good relationships with DATAMEDICA’s colleagues 
and other professionals of the area; 
 Know the principal methodologies used in the conception, development and 
implementation of clinical studies; 
 Acquire competences for protocols’ conception, study design and implement 
methodologies to avoid bias during study conduction. 
More specifically, this internship aimed to obtain knowledge and practice on the following tasks: 
 Perform all the tasks according with the Good Clinical Practices (GCP) and with the Host 
Company’s procedures; 
 Acquaint with the Host Company dynamics; 
 Support the Host Company in all its projects; 
 Perform all the tasks in a careful and precise way and within the predefined deadlines; 
 Participate in training activities; 
 Submission of clinical studies to competent authorities; 
 Implementation of clinical studies at the study’s sites; 
 Perform co-monitoring visits at the study’s sites; 
 Acquire important competences in quality assurance, medical writing, data management 
and statistics related to Clinical Research. 
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1.2 Host Company  
CROs are external and independent entities that supply consultancy services to all players of 
Clinical Research area. DATAMEDICA, Serviços e Consultoria em Bioestatística, Lda., is one of 
the most relevant CRO in national territory, supporting Pharmaceutical Industry, Health Care 
Professionals, International CROs and other entities dedicated to Clinical Research area. 
At the date of its creation, in 1996, DATAMEDICA just provided biostatistical consultancy services, 
however, in response to the Market’s needs, the consultancy services were extended to a much 
broader number of services. Nowadays, DATAMEDICA supports Clinical and Epidemiologic 
Investigation, namely Protocol development, Case Report Form (CRF) design, Study Logistics 
definition and implementation, Study Submission to Competent Authorities (CA), Study Monitoring 
and Back-Office support, Data Management (DM) and Statistical Analysis. It also offers Medical 
Writing (MW) services and support of abstracts/articles’ submission process, Meta-Analysis, Expert 
Panels, Advisory Boards and Consensus services (preparation, development, implementation and 
support) and Pharmacoeconomic studies. Due to the quality of its services, flexibility and 
adaptation capacities of its multidisciplinary team, DATAMEDICA has achieved a strong reputation 
among national and international Clinical Research stakeholders. 
During this internship, DATAMEDICA provided services to more than 25 Pharmaceutical 
Companies, Health Professionals Societies and CROs from Europe and United States of America.  
Recently, DATAMEDICA incorporated the INTERWAY Group, created in 2003 and which focus is 
on the development and implementation of several projects and seeking of new opportunities in 
emerging markets, mainly in Sub-Saharan Africa. Guided by a policy of continuous expansion and 
development, the Group has already economic activities and operations in Angola, Mozambique, 
Sao Tome and Principe, Brazil and Portugal, with several areas of activity: Workspace 
Optimisation, Logistics, Operation and Management of Shopping Centres, Interior Design and 
Architecture, Technology, Health, Luxury Retail and Corporate and Business Consulting. 
DATAMEDICA has an Administration Board, a Financial and Administrative Department, an 
Executive Management and Commercial Department, and a Scientific Department. The Scientific 
Department is the main core of DATAMEDICA’s technical and scientific work and encompasses 
most of the activities related to clinical studies. The Research & Development Unit is mainly 
responsible by clinical studies design, bibliographic research to support clinical studies and 
development of clinical studies’ protocol, both as CRF design and informed consent preparation. 
Clinical Operations Unit is more focused on submission and monitoring of clinical studies. DM & 
Statistical Unit performs all the tasks related to data management, such as database design, query 
resolution and database cleaning, also participating in CRF design. Regarding statistics, its main 
focus concerns statistical analysis data of clinical studies, critical interpretation of the data, and 
statistical reports development. DATAMEDICA is also involved in other activities, suchlike sample 
size calculation and respective rational, statistical analysis plan conception, interim analysis 
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performance, and protocol support regarding statistical section. Medical Writing Unit is in charge of 
abstracts, posters and articles, both development and submission, oral communications support, 
advisory boards/ expert panels transcription and report. At last, Regulatory Affairs & 
Pharmacovigilance Unit performs mainly outsourcing activities on the scope of pharmacovigilance. 
The organisational chart of DATAMEDICA is displayed at Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. DATAMEDICA’s organisational chart (DATAMEDICA’s Internal Procedure) 
 
It is important to notice that some of these departments are formed by just one person due to the 
size of the company. So, this is a small company with 10 employees, which facilitates social 
interactions between colleagues and the crossing of information in the different areas of expertise 
and contributes to the maintenance of collaborators’ continuous learning process. Although each 
worker has his own area of expertise, all the projects developed and in progress are discussed by 
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the team and a multi-task ability to follow the projects and to perform the tasks required is 
mandatory.  
A biweekly meeting is held at DATAMEDICA with all the operational collaborators. The main 
purpose of this meeting is to discuss DATAMEDICA’s projects, mainly concerning a brief status of 
each project and an analysis of critical points or raised problems or issues. These meetings were 
implemented by Quality Assurance Department and helped sharing the work of each collaborator 
to the team and discuss different opinions, experiences and resolutions, while receiving feedback  
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2. STATE OF THE ART – CLINICAL RESEARCH 
As DATAMEDICA performs their services in the Clinical Research area, it is important to give to 
the readers an introduction to this field. Therefore, this chapter will present a global overview of this 
area introducing its main features. Moreover, the stakeholders and their roles in Clinical Research 
will be summarized as well as the regulatory framework. Competent Authorities (CA), responsible 
for the interventional studies and health technologies’ evaluation will be also introduced. At last, the 
current state of art of Clinical Research in Portugal compared to Europe will be presented. 
 
Clinical Research is an enormous field of investigation and its development began because human 
civilisations always had a special interest in the health of Man and other animals, which led to the 
discovery of a large number of therapeutic agents in nature. (1). Clinical Research has been 
growing up and, due to the involvement of a large number of pharmaceutical companies and many 
academic institutions, there was a major progress in the regulation field, in the knowledge of the 
diseases’ processes and in the creation of health technologies to prevent, control or eliminate it. 
Any systematic study conducted in humans with one of the following objectives can be defined as 
Clinical Research: to discover or verify the distribution or effect of health factors, conditions or 
health outcomes and/or to understand the causes, progress and consequences of diseases; 
improve prevention, diagnostic and therapeutic interventions (methods, procedures and 
treatments) by studying its performance, safety, efficacy and effectiveness, efficiency, accessibility 
and quality (2, 3).  
Clinical Research gives an important assistance to health care by finding evidences that support 
and allow good clinical decisions. Evidence Based Medicine (EBM) is a medicine practice in which 
decision-making is optimized by the use of evidence from well designed and conducted Clinical 
Research studies. Evidence may be obtained with different strategies: meta-analysis, systematic 
reviews, randomised Controlled Trials (RCT), non-interventional studies (such as case-control or 
cohort studies), non-analytical studies (such as case reports or case series) and experts’ opinion. 
However, these studies have different levels of evidence strength and, therefore, depending on the 
question, the most evident and strong strategy will vary. Due to their design and methodologies, it 
is understandable that meta-analysis and systematic reviews, followed by RCT, have a higher level 
of evidence and represent an important research activity with the potential to improve the quality of 
health care and control costs through an accurate comparison of alternative treatments. Yet, all the 
studies should be assessed regarding their validity, results and relevance (4-6). 
During the internship, DATAMEDICA provided services in the scope of RCT, interventional studies 
with medical devices, non-interventional studies and experts’ opinion panels, with great validity in 
Clinical Research and very important to EBM. This report will try to cover all the relevant points of 
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these studies, which represents a great challenge due to all the factors involved in health sector 
and due to all the specifications of the transversal areas tangled with Clinical Research. 
Clinical Research is accomplished within a highly regulated environment because it involves 
human participants, human material and/or human data. The participation of human subjects raises 
several ethical issues once their safety and rights must always be protected and guaranteed. 
Based on the Nuremberg Code, World Medical Association (WMA) compiled the Declaration of 
Helsinki, which is a set of ethical principles for Clinical Research involving human participants that 
includes research on identifiable human material and data. Even though Declaration of Helsinki is 
not a legally binding document under the international law, its authority is supported by its influence 
on the development of national or regional legislation and regulations (2). 
Additionally, the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) creates documents that make 
recommendations regarding scientific and technical aspects of drugs’ development and 
registration. ICH Guidelines preparation involves the regulatory authorities and the pharmaceutical 
industries of several countries all over the World, with the final objective of achieving a greater 
harmonisation between all of them, ensuring that safe, effective, and high quality medicines are 
developed and registered in the most resource-efficient manner (7). It is important to refer ICH 
Guideline E6 “Guideline for Good Clinical Practice” as it is an international reference that gives 
support on the designing, conducting, recording, and reporting studies that involve human 
participants regarding mainly ethic and scientific quality considerations (8). Training on this 
guideline is mandatory for all the involved individuals and entities in Clinical Research area, mainly 
to those involved in interventional clinical studies, such as Clinical Trials. 
In Europe, European Commission (EC) creates legislation applied to the pharmaceutical sector, 
which is compiled at Eudralex. European Medicines Agency (EMA), a decentralised agency of the 
European Union (EU), is responsible for the scientific evaluation and continuous supervision of 
medicines for human or veterinary use in the EU. Mainly, EMA scientifically evaluates applications 
for marketing authorisations in EU through centralized procedure, providing an opinion on the 
submission application helping the EC’s final decision, and coordinates the EU’s 
pharmacovigilance system (9). 
The most important European directives and regulations regarding Clinical Research are: 
 Directive 2001/83/EC and Regulation (EC) No 726/2004, which define the requirements 
and procedures for the marketing authorisation of human use medicines and give 
guidelines on the continuous supervision of products after marketing introduction; 
 Directive 2001/20/EC and Regulation (EU) No 536/2014, which define the requirements for 
conducting Clinical Trials in the EU; 
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 Directive 2005/28/EC, which defines the principles of GCP for Clinical Trials on human 
participants involving investigational medicinal products for human use, as well as the 
requirements for authorisation of the manufacturing or importation of such products; 
 Directive 2007/47/EC, which amend Directive 90/385/EEC on the approximation of the 
laws regarding active implantable medical devices, Directive 93/42/EEC concerning 
medical devices and Directive 98/8/EC concerning the placing of biocidal products on the 
market. 
Other European directives and regulations are important but are specific to other scopes, such as 
medical devices development, medication manufacturing, distribution and labelling, 
pharmacovigilance, orphan medicinal products, between others.  
In Portugal, the monitoring, regulation and supervision of medicines, medical devices, cosmetics 
and body care products is a responsibility of INFARMED (Autoridade Nacional do Medicamento e 
Produtos de Saúde) and these are done according to the highest quality and safety standards. This 
institution also assures the access of health professionals and citizens to effective and safe 
medicines, medical devices, cosmetics and body care products with the required quality (10). 
Besides INFARMED, clinical studies must be assessed by CEIC (Comissão de Ética para a 
Investigação Clínica), which is the national ethics committee for Clinical Research. CEIC is 
responsible to assure the rights, safety and well-being of human participants (11), and by CNPD 
(Comissão Nacional de Proteção de Dados), which is a national public institution that controls and 
verify sensible personal data handling, assuring the compliance with human rights and legal 
regulations (12). 
Most relevant Portuguese legislations regarding Clinical Research are: 
 Law No 21/2014, which is a transposition of Directive 2001/20/EC and that have recently 
revoked Law No 46/2004; 
 Law No 102/2007, which is a transposition of Directive 2005/28/EC; 
 Law No 67/98, which establishes the principles and requirements for personal data 
handling and free movement of personal information and it is a transposition of Directive 
95/46/EC; 
 Law No 145/2009, which establishes the rules to medical devices investigation, 
manufacture, commercialization, vigilance and publicity and it is a transposition of Directive 
2007/47/CE. 
Besides this regulatory framework, INFARMED, CEIC and CNPD have published several guidance 
documents establishing the requirements regarding specific considerations such as the request for 
clinical studies’ authorisation, notification of substantial amendments, data handling, and studies 
results’ publication. 
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According to European directive 2001/20/EC, Clinical Trials are defined as “any investigation in 
human subjects intended to discover or verify the clinical, pharmacological and/or other 
pharmacodynamic effects of one or more investigational medicinal product(s), and/or to identify any 
adverse reactions to one or more investigational medicinal product(s) and/or to study absorption, 
distribution, metabolism and excretion of one or more investigational medicinal product(s) with the 
object of ascertaining its (their) safety and/or efficacy” and this definition has been transposed into 
National Law No 21/2014 (3, 13). 
Additionally, National Law No 21/2014 distinguishes Clinical Trials from other clinical studies, which 
are any systematic studies, conducted on humans or through individual health information, 
intended to discover or verify the distribution or effect of health factors, health conditions or health 
outcomes; health course and disease evolution; and to understand and evaluate the performance 
and/ or safety of clinical technologies or health care, through biological, behavioural, social or 
organizational aspects. The following are examples of clinical studies: a study that evaluates an 
intervention which is different from clinical practice; a study involving medical devices; a study of 
alimentary regimens or a study involving cosmetics and body care products (3). Clinical studies 
also include non-interventional clinical studies, in which medicines or medical devices are used 
according with their marketing authorisation or conformity assessments’ procedures, respectively, 
and the participants’ inclusion in a particular therapeutic strategy just depends on clinical practice 
and is not decided in advance by a Clinical Study’s protocol. Also, during non-interventional clinical 
studies, the prescription of a drug or the utilisation of a medical device is clearly independent from 
the decision to include the patient in the study, no monitoring or additional diagnostic procedures 
are applied and epidemiological methods are used for the analysis of the collected data (3, 14). 
Pharmaceutical industries are the main boosters of Clinical Trials aiming to obtain data on the 
safety and efficacy of medicinal products that are being developed. Approximately 40% of the 
Clinical Trials in the EU are being conducted by academics, hospital or research networkers (often 
referred to as 'non-commercial Sponsors'), usually, to improve and compare treatments with 
authorised medicines (15). DATAMEDICA provides services to clinical studies sponsored by 
pharmaceutical industry and to Investigator Initiated Studies (IIS), which are studies initiated by 
academic or non-academic institutions or by health professionals, without commercial interests, 
although often supported by pharmaceutical industries. In IIS, the investigator assumes 
responsibility regarding study’s initiation, management and/ or financing, while conducting the 
study (8). IIS principal aim is to improve the scientific knowledge and patient care and may be 
focused on potential diagnostic and therapeutic products not attractive or without commercial 
interest. This allows to provide the necessary evidence to the conception of treatment guidelines 
and to assure the proper use of the resources. Typical examples of IIS are proof-of-concept 
studies, rare diseases (orphan medicines), diagnostic or therapeutic interventions comparison, 
surgical therapies or novel indications for already marketing products (16). As referred before, IIS 
are supported by pharmaceutical companies, which benefit with the collection of additional safety 
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and efficacy data and useful information to support new indications or to be included on the 
marketing authorisation dossier. 
To enhance studies’ efficiency, while saving resources, Sponsors of clinical studies rely on 
Contract Research Organizations (CROs) like DATAMEDICA. According to ICH E6, a CRO is 
defined as “a person or an organization (commercial, academic, or other) contracted by the 
Sponsor to perform one or more of a Sponsor's trial-related duties and functions”, which must be 
specified in writing. However, the Sponsor have the ultimate responsibility for the quality and 
integrity of study’s data (8). 
CROs’ main objective is to improve the efficiency and financial performance of the Client, while 
providing more benefits to authorities, health professionals and citizens. These organisations 
provide services with the intent of improving and accelerating clinical studies, resulting in a superior 
return on investment (ROI) for the new product, reducing cycle time, while increasing the quality of 
study’s data (17) and maintaining the independency from commercial or other type of interests. 
Nowadays, there are CROs that provide a full service support, others that are specialised in a 
distinct area of Clinical Research, and Site Management Organisations (SMOs) that support the 
centres in clinical studies-related issues (17). 
Regarding Clinical Research state of the art in Portugal, the number of Clinical Trials’ application 
submissions to INFARMED is slowly decreasing. Between 2006 and 2014, the number of 
submissions decreased from 160 to 127, reaching the lowest number of Clinical Trials’ submission 
in 2011, with only 88 submissions. A large part of the submitted studies are confirmatory or post-
market multicentre Clinical Trials and, approximately 20% of the Clinical Trials are phase I or II.  
In 2013, the majority of the Clinical Trials conducted in Portuguese sites were focused on oncology 
and immunomodulators therapeutic areas (42%), followed by anti-infectives (13%) and 
cardiovascular system (11%) (18). In this period, approximately 93% of the submissions made in 
each year came from pharmaceutical industries, compared to IIS’s submissions which are much 
less in Portugal. Thus, in 2013, pharmaceutical industry submitted 98 Clinical Trials to evaluation 
versus 16 Clinical Trials submitted to evaluation by academic Sponsors. When we assess the 
number of conducted Clinical Trials at 2013, Portugal had 159 active Clinical Trials, a very small 
number compared to Spain which had 858 Clinical Trials and to United Kingdom with 832 Clinical 
Trials (18, 19). 
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Figure 2. Clinical Trials’ authorisation requests to INFARMED (19) 
 
Regarding Portugal approvals’ times, clinical studies application approvals may take 60 days, 
theoretically. However, the real period can exceed 70 days, in average, when taking into account 
the approval time taken by the Administration Board of the sites (18). The inefficiency of the 
assessment process by all the involved parties such as CNPD and Site’s Administration Boards is 
one of the critical aspects that have diminished Portugal competitiveness versus other European 
countries. 
In summary, Clinical Research is a complex network with several players, all of them with specific 
responsibilities and functions. An efficient communication and interaction between all these players 
is essential to enhance the number of clinical studies in Portugal, bringing the country “back to the 
competition”. The increase of Clinical Research conducted in Portugal would bring a lot of benefits 
to our country and its citizens namely an earlier access to innovative and better treatments and 
also, concerning social and financial benefits, Clinical Trials would increase employment 
opportunities and enhance savings on the health spending. 
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Figure 3. Stakeholders of Clinical Research 
 
 
More information can be given to introduce Clinical Research and all its specific branches as 
studies’ conception, Clinical Trials’ submission and monitoring, medical writing, pharmacoeconomic 
studies or other. However, to facilitate the comprehension of the reader, this specific information 
regarding the framework of each Clinical Research branches will be given separately in the next 
sections. 
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3. INTERNSHIP ACTIVITIES 
The main focus of this chapter is to describe the activities developed during the 7-months 
internship.  
The internship was much diversified and provided me the opportunity to perform a very large range 
of activities since the initial conception and development of the clinical studies to study results’ 
analysis, reports development, along with transversal activities such as medical writing, quality 
management system (QMS) revision, and pharmacovigilance. Therefore, this chapter is divided in 
8 sections, each related to the activities developed during the internship: Conception & 
Development of Clinical Studies; Studies’ Submission; Monitoring Activities; Data Management; 
Pharmacoeconomic Studies; Advisory Boards and Expert Panels; Medical Writing and Quality 
Management System related activities. In each section, the procedures usually followed to achieve 
the task and its specific aims will be described. A brief introduction to the scope and the relevance 
will be given to help the understanding of these themes. 
Before internship activities description, it is important to mention that prior to receiving any 
information related to DATAMEDICA‘s Projects or Clients, every collaborator must sign a 
Confidentiality Agreement concerning all sensitive and confidential information that the collaborator 
can manage while working at DATAMEDICA. In this report, it would not be mentioned or shared 
Clients’ names, study’s protocol or health products information, nor any personal data of study 
participants. However, information of public access, such as Clinical Trials names or general 
information about them, may be shared. 
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3.1 Conception & Development of Clinical Studies 
The conception of a Clinical Study (Interventional or Non-Interventional) begins with the formulation 
of a relevant hypothesis. Usually, the Client wants to support a new marketing authorisation, a new 
indication or a new formulation for a medicine already in the market or wants to understand a 
specific feature on the real population. After the objective’s definition, the experience of 
DATAMEDICA’s collaborators is essential to help the Client on the definition of study design and 
methodology regarding its main goal: should we perform a Clinical Trial or a non-interventional 
one? Should a Clinical Trial have a parallel design or should it be cross-over? Should it be double-
blind? Randomised? 
There are a large set of questions that must be answered when conceptualizing the study, which 
affects the study’s results and quality, as well as the study’s budget, without neglecting the rights 
and safety of human participants. The definition of an adequate design is crucial, once that can 
negatively influence the quality of the data and diminish study’s results validity. Therefore, the 
conceptualisation of a study should involve both the Client, an expert in studies’ designs and 
methodology, a biostatistician and a health professional specialised in the area. It is important to 
understand the Client’s goals and the study’s specific objectives. 
Study’s endpoints can be divided in two: efficacy and safety endpoints. Primary efficacy endpoints 
must allow to assess and give clinically relevant and undeniable evidence directly related to the 
study’s primary objective (20). Generally, there is just one primary efficacy endpoint for each study. 
However, in specific cases, a multiple primary endpoint could be defined, which will imply a 
different statistical methodology, than the commonly used. To support the selection of the endpoint, 
EMA published several directives focused on specific diseases and research that give 
recommendations for endpoint’s definition as well as other important considerations that should be 
taken into account (21). 
During Clinical Trial’s conception, I performed a bibliographic revision about the theme in question, 
followed by a self-training that included: prevalence and incidence of the condition in Portugal, 
Europe and worldwide, signs and symptoms, causes, methods of diagnostic, current treatments 
and follow-up procedures. A profound knowledge on the study thematic is helpful to assess the 
viability of a specific design. In this case, a cross-over design was not viable because the 
progression of the disease is variable and therefore it was not possible to assure that the patients 
will exhibit a similar severity of the disease during study conduction. 
Regarding the same project, it was decided that both health professionals and patients should not 
know the treatment that each patient received (double-blinding) because clinical response to the 
treatment was subjective and dependent on patient’s opinion. In this specific study, a logistic 
problem was raised with this decision because the Investigational Medicinal Product (IMP) had a 
different formulation than the active comparator and, for that reason, DATAMEDICA recommended 
the double-dummy technique, which is used when the two treatments cannot be made identical. 
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Study’s evaluation procedures and their schedule are dependent on the mechanism of action of the 
investigational product and on the study objectives. During evaluation procedures, it is really 
important to discuss with a health professional the possible exams, procedures and understand the 
clinical practice in Portuguese centres. However, besides the support of the health professional, an 
exhaustive bibliographic revision must be performed. National health system publishes guidelines 
focusing a specific disease regarding both diagnostic and treatment methods. 
Another relevant point that must be addressed during the study’s conception phase is the target 
population and the sample size. In the studies that DATAMEDICA have managed, the definition of 
the target population was clear. However, the selection of eligibility criteria requires an extensive 
literature revision in order to comprehend the product mechanism of action, influencing factors and 
the disease. All the possible factors that could change the study’s results must be controlled and 
minimized to maintain sufficient homogeneity and, therefore, to allow a precise estimation of 
treatment effects (20). 
Regarding sample size, how many participants should be included on the study to achieve its 
objectives? Sample size should be large enough to give reliable answers to the study endpoints 
and to allow to reject or accept the initial study’s hypothesis (20). Sample size determination 
requires the previous definition of the primary efficacy endpoint, the null and alternative hypothesis 
and it depends on the size of the expected effect on the primary efficacy endpoint and its variability, 
the probability of wrongly reject the null hypothesis (the type I error), and the probability of 
incorrectly fail to reject the null hypothesis (the type II error). ICH guidelines recommend the use of 
type I error set at 5% or less and the use of a type II error set at 10% to 20% (20). During the 
internship, I had the opportunity to support the medical statistician during sample size calculation, 
once that it was necessary to define the prevalence of the disease and, for that, I had to perform a 
bibliographic research to find the update and reliable data. 
When the study’s objectives and methodology are defined, the development of study documents 
can begin. The most important document is the Study’s Protocol, which describes the study’s 
objectives, design, target population, methodology and statistical considerations (13). In the 
Protocol, it is also given an introduction to the theme in question and the study rationale is detailed, 
as well as ethics considerations and other administrative relevant points. ICH E6 “Good Clinical 
Practice” defines the main topics that must be addressed on the Clinical Study’s Protocol (8).  
The Study’s Protocol will support the appraisal of the Competent Authorities and will support the 
chores and duties of the Study’s Team since participants’ recruitment until close-out. Therefore, a 
good Protocol facilitates external review of the study, its correct conduction and final reporting (22). 
During the internship, I had the opportunity to create several study documents such as Study’s 
Protocol, Informed Consent Form (ICF), Patient Information Sheet (PIS) and CRFs. I also had the 
opportunity to support other documentation development regarding non-interventional studies. 
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This experience enabled me to acquire more knowledge about studies’ methodology, such as 
randomization and blinding techniques, along with more specific understanding of biostatistical 
considerations and also the particular structures and functions of study’s documentation. 
The implementation of a Clinical Trial requires an enormous logistics that must assure that all the 
possible risks or failure are identified prior to the implementation and that all the possible actions to 
minimize the possibility of risks’ occurrence are taken. Besides these, there are other tasks that 
must be conducted before the submission of the trial to all the required entities, such as the 
definition of the medicine circuit, the development of medicine batches according to Annex 13 of 
the 4th volume of EU Guidelines to Good Manufacturing Practice, Insurance Certificate contract, 
and the purchase of specific items to be given to the sites (e.g. scales, blood pressure monitors, 
stadiometers and pregnancy tests). 
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3.2 Studies’ Registration and Submission 
Studies’ registration is important to increase transparency, avoid unnecessary duplication of 
Clinical Research, facilitating the identification of ongoing, completed or terminated studies and 
allow us the overview of all Clinical Trials and also the performance of statistical analysis regarding 
general picture (22). Regarding the submission of the clinical studies to Ethics Committees or to 
Competent Authorities, such as INFARMED, the evaluation of the benefits and risks involved in the 
study must be addressed mainly regarding the Study’s Protocol, the study team and the centres 
proposed, the Investigator Brochure, the ICF and the Insurance Certificate (13). 
During the internship, DATAMEDICA participated on the registration and submission to ethics 
committees, INFARMED and Administration Boards of several clinical studies, such as Clinical 
Trials and non-interventional studies. The graphic 2 shows the number of registrations and 
submissions performed by me during the internship and the table 1 summarizes the activities that I 
performed in each one of them. 
 
Figure 4. Number of Registrations and Submissions of Clinical Studies performed during my 
internship 
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Table 1. Specific tasks that I have performed during my internship, regarding registration and submission of 
Clinical Studies 
Activity Specific tasks performed/ assisted 
EudraCT 
Registration 
 Filing of online form to obtain the EudraCT number for CTs. 
 Completion, revision and modification of XML files support. 
CNPD Submission 
 Filing of online forms. 
 Send of study documents (study synopsis, CRF and informed 
consent) to CNPD. 
 Reply to requests for additional information regarding the relevance to 
collect an ethic variable. 
 Follow-up of the processes’ evaluation. 
INFARMED 
Submission 
 Preparation of cover letters. 
 Documents archive in a folder scheme according to INFARMED 
directives. 
 In person delivery of CTs submission. 
CEIC Submission 
 Preparation of cover letters.  
 Documents archive in a folder scheme according to CEIC directives. 
 In person delivery of CTs submission. 
Study Sites 
Submission 
 Sites’ contact to request local requirements and applicable templates 
before studies’ initiation. 
 Preparation of cover letters. 
 Discussion and development of financial agreements. 
 Documents archive in a folder scheme according to Site’s specific 
directives. 
 Filing of site specific forms and adaption of Site’s templates. 
 Sending additional documentation and answering the questions raised 
during process evaluation. 
 Follow-up of the processes’ evaluation. 
 
3.2.1 Studies’ Registration 
In Europe, CT registration is an actual requirement based on ethical and scientific reasons and 
must be carried out before the inclusion of the first subject. EudraCT is the European Clinical Trials 
Database, an open public database, which collects information of all Clinical Trials involving 
investigational medicinal products occurring in, at least, one site in the EU (23).  
To apply for a EudraCT number at the EudraCT website, information about the requestor's 
organisation and the Clinical Trial in question is required: 
 Requestor's organisation name, town/ city and country; 
 Sponsor's Protocol code number; 
 Contact person’s name and e-mail to whom the EudraCT number will be sent; 
 Whether the Clinical Trial is contained in a Paediatric Investigation Plan (PIP) or whether it 
will be conducted in a third country (outside of the EU/EEA); 
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 The Member States where it is anticipated that the trial will be conducted. 
After submission of the EudraCT Number form, I received an e-mail with the number assigned to 
the Clinical Trial, which had the format YYYY-NNNNNN-CC, where YYYY is the year the number 
was issued; NNNNNN is a six digit sequential number, and CC is a check digit (23). 
At EudraCT website, the filing of the XML file is also performed. This is a form with several 
questions related to the Clinical Trial essentials for the submission of a Clinical Trial application to 
the competent authorities and to the ethics committees. XML file is in a specific format that can 
only be open at EudraCT website, however it also enables to save the information in PDF format.  
The XML complies all the CT’s information required by the authorities to assess the study and to 
enter the details of the trial into the EudraCT database, as required at CT directive 2001/20/EC 
(24). More specifically, it contains information regarding the trial and its Sponsor identification and 
also information about medication, target indication and population, the selected sites and 
investigators. 
The filing of the XML file is a simple but extended process. The form is composed by10 sections, 
each one composed by a variable group of questions. Several questions are dependent of one 
another, i.e., according to the answer given we can have less or more questions to answer. To 
facilitate the process and to help the filing, the site raises alerts when the information is not correct 
or consistent. It only allow us to submit a section of the form when all the queries raised are solved. 
 
3.2.2 Studies’ Submission 
After the development, revision and approval of all the relevant documents, the next step is the 
submission of an application to the CA. For the initiation of a Clinical Trial or a Clinical Study with 
Medical Devices, the application must be submitted to INFARMED, CEIC, CNPD and Study’s Sites 
Administration Boards. Regarding Non-Interventional Studies, the application just needs to be 
submitted to CNPD, Study’s Sites Administration Boards and Local Ethics Committees. 
CNPD submission is accomplished electronically, via CNPD website (www.cnpd.pt) by completing 
a form with the requested information related to the Investigational Study. During the internship 
period, DATAMEDICA performed several CNPD submissions, therefore completing CNPD’s form 
in order to submit clinical studies was one of the tasks that I performed at DATAMEDICA. 
Application assessment by CNPD focuses on the management of sensitive personal data, such as 
personnel and clinical data. Therefore, CNPD’s application includes the following information:  
 Identity and information of the study’s Sponsor; 
 Identity and contacts of the person/ entity responsible for data management;  
 Type of data collected (philosophical convictions, ethnicity, private life, health data, genetic 
data, or other personal data); 
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 Type of data collection (direct, such as attendance, by phone, form, questionnaire, internet, 
or through indirect collection); 
 Protocol synopsis; 
 Informed Consent Form and Patient Information Sheet; 
 Study’s variables list/ URL of e-CRF. 
After the submission, the responsible person, which can be the Study Monitor, must follow the 
approval process so that prompt attention can be given to any request for additional information, 
clarification or objections. 
During my internship, I collected all the submission dates of applications to CNPD and the dates 
when DATAMEDICA received the final CNPD’s authorization, to allow me to calculate the mean 
time obtained between these two points (submission and authorization), which is 138 days. Some 
applications included in this calculation had long evaluation process due to the raise of questions 
by CNPD. Even being a common willingness of the applicant to rapidly answer the questions, there 
is no limit period to give a reply, which is not the case when we talk about INFARMED or CEIC that 
have a legal limit period to the applicant reply questions raise during the evaluation process. 
Regarding CEIC and INFARMED evaluation, the main focus is the quality of the scientific 
background of the protocol and the capacity of the investigational sites and investigators to conduct 
the study. According to the new Portuguese Law (Law No 21/2014), the request for a Clinical Study 
authorisation to INFARMED and to the Competent Ethics Committee (CEC) will be performed by 
the electronic platform RNEC – Registo Nacional de Estudos Clínicos (3). This platform is being 
designed to register and publicize clinical studies, allowing the interaction between different 
stakeholders, and with the main objective to facilitate the development of clinical investigation and 
enhance its disclosure to patients, health professionals and investigators. However, this platform is 
still under development and, therefore, the requests of clinical studies authorisations have not 
changed yet, and are still performed as described below: 
CTs submission to INFARMED must follow the requirements described in “Instructions for 
applicants for the request of a Clinical Trial Authorisation, Substantial Amendment submission, 
declaration of the end of a trial, SUSAR notification and annual safety report submission process – 
16th June 2014” and it should be performed according to “Detailed guidance on the request to the 
competent authorities for authorisation of a Clinical Trial on a medicinal product for human use, the 
notification of substantial amendments and the declaration of the end of the trial (CT-1) (2010/C 
82/01)”. 
INFARMED requests a set of documentation, from which the most relevant documents are: 
 XML File, which summarize relevant information of the CT; 
 Signed CT Protocol; 
 Investigator’s Brochure or Summary of Product Characteristic; 
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 List of all CTs involving the concerning Investigational Medicine Product (IMP); 
 Financial memory; 
 Insurance certificate. 
This documentation must be saved on a CD-ROM according to a schematic organisation 
predefined by INFARMED in “Instructions for Applicants”. 
The request for a CT authorisation to CEIC is similar to what was mentioned before. The request 
must comply with “Instructions to applicants for the format and content of the request for a Clinical 
Trial authorisation process with medicinal products for human use, notification of amendments, 
adverse events notification and declaration of the end of Clinical Trial – June 2005” and with CT-1 
Guidance. For CEIC evaluation, the application submitted must be completed and the most 
relevant documents are the following: 
 Signed CT Protocol; 
 Experimental medicine circuit; 
 Informed Consent Form and Patient Information Sheet; 
 Patients’ recruitment modality; 
 Financial memory and final draft of the Financial Agreement and Clinical Trial Agreement; 
 Ethical evaluation from the Coordinator Investigator; 
 Authorisation from the Head of Department/ Service; 
 Declaration regarding study site conditions and study team constitution, and declaration 
from the Head of Pharmaceutical Services certifying service’s conditions to conduct the 
study; 
 Curriculum Vitae (CV) of the Coordinator Investigator and of all the PIs. 
As the submission to INFARMED, CEIC submission must be delivered in a CD-ROM format saved 
according to a schematic organization defined by CEIC in “Instructions for Applicants”. 
During the evaluation process, INFARMED and CEIC may raise questions and the CRA must 
inform the Sponsor of the situation. A response to the authorities must be sent as soon as possible.  
Nevertheless, the final authorisation to start the Clinical Study at a specific investigational site 
depends on the site Administration Board’s approval.  
Furthermore, the selection of the clinical sites is another important process because the centres 
are crucial for performing the study: they conduct the study according with the Protocol and create 
precise and reproducible clinical data in a timely and safe manner. Besides assessing 
Investigators’ qualifications regarding education, training and experience through their CVs, the 
suitability of sites’ material, human resources, infrastructures and population should be evaluated. 
Centres’ selection depends on study protocol complexity, types of procedures required, availability 
of experienced staff, budgeting issues and, sometimes, on previous knowledge of centres’ 
performance (25). 
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DATAMEDICA collaborates with a large range of public and private health institutions in the scope 
of Clinical Research. During the internship, I could observe the differences between studies’ 
centres. Some centres, like big hospitals or specialised clinics, have a larger team allocated just for 
the coordination of clinical studies conducted at their centre and they give support to the study 
team by assisting on study visits schedule, aid on getting the collaboration of the different 
departments involved, help on filing of the CRF and in adverse events report or by recording study 
medicines’ administration and coordinating patient’ visits schedules. Also, this team provides aid to 
the CRA on the elaboration of feasibility surveys before sites’ selection, on the contact with the 
departments involved in the study, on the elaboration of the Clinical Trial and financial agreements, 
on the collection of relevant documents, and facilitating monitoring visits and the conduction of 
Source Data Verification (SDV). Furthermore, in these centres, the administrative bureaucracy is 
better defined and works like a “well-oiled machine”, once there are checklists that define what 
must be submitted to the sites’ Administration Boards. There are established templates to be 
completed during studies’ submission, and each sites’ departments/ services also have their own 
templates and specific procedures. A good example is the pharmacy, where the reception, 
dispense, return, accountability and destruction of medication take place, which are crucial steps 
and, therefore, are tightly controlled by the Sponsor and also by the centres’ pharmacy staff.  
However, in some cases, such as in Unidades de Saúde Familiares (USFs) or small hospitals, that 
still not conduct clinical studies regularly, the Sponsor or the monitor directly contacts with the 
study team and the investigators are responsible to collect relevant documentation, submit the 
Clinical Study to the Administration Board and to manage the collaboration between all the sites’ 
departments and between study team, besides conducting and complying with the Protocol. 
The request for authorisation of a Clinical Study to a centre’s Administration Board is a case-by-
case process and must follow the centre’s specific requirements. If the site does not have specified 
requirements for submission, the process must contain all the relevant documentation to support 
the evaluation process by the administration board, such as Clinical Study Protocol, ICF and PIS, 
CRF, authorisation letters of INFARMED and CNPD, favourable opinion letter of CEIC, head of 
department authorisation letter, CVs of PI and sub-investigators, draft of financial agreement and 
insurance certificate. 
Site Initiation Visit (SIV) and inclusion of study participants into a Clinical Study must only be 
performed after all the approvals are in place, either received by the Sponsor or by its 
representative, namely, a CRO. 
While supporting Clinical Operations unit, I have noticed two different dimensions: clinical studies in 
which the Sponsor is a multinational entity and where the study will be conducted in other countries 
besides Portugal; and clinical studies sponsored by a small Portuguese or Iberian entity and where 
the study will only be conducted in Portugal. Regarding the first ones, the Sponsor has a 
submission pack already prepared and the CRO only has to adapt some documentation to the 
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national law, language and scope, such as Study Synopsis, XML File and documentation that will 
be given to the participants, besides organizing the documentation that will be submitted to 
INFARMED and CEIC according to their own “Instructions for Applicants”. When given support to a 
national entity, the CRO must help the Sponsor regarding documentation collection, identifying the 
necessary documents or collecting it proactively. 
The agreement of the insurance certificate is a legal requirement for the conduction of Clinical 
Trials and represents a very expensive item. Due to the lack of knowledge on the conduction of 
CTs, small companies do not know how to achieve the insurance and do not understand why it is 
so expensive. 
In addition, DATAMEDICA’s CRAs have faced some difficulties during a CT submission and 
implementation at a USF, because this facility does not have the same characteristics as a 
Hospital. A good example of these problems is the lack of a pharmaceutical service at the USF, 
which is a requirement to CT´s conduction, according to Law No 21/2014 to receive, storage, 
dispense, collect and destruct/ return the study medication. To pass through this situation, the 
study medication can be delivered to a qualified pharmaceutical service such as a local pharmacy. 
As similar to hospital pharmacies involved on a CT, the local pharmacy must have a qualified 
pharmaceutical responsible to receive, dispense, control and register the medication, a restrict 
access to the local of archiving study documentation and a fridge/ cabinet to storage the 
medication with a system that register the storage conditions (temperature and humidity). 
Financial Agreements are also difficult to create. The discussion between all the involved parts is 
time consuming. CROs struggle with more difficulties when creating financial agreements in the 
scope of an IIS due to the lack of regulation for this type of studies and when performing financial 
agreements with USFs. In these specific centres, it is frequent the absence of a template that 
specifies the site requisites and there is no support documentation that assists the submission 
process. 
 
3.2.3 Submission of Substantial and Non-Substantial Amendments 
During the internship, I supported the submission of substantial and non-substantial amendments. 
The performance of amendments regarding the Clinical Study after its beginning is allowed 
according to the European Regulation and National Law (3, 26). A CT amendment may arise from 
alterations of the protocol or due to new scientific information that support the study. Amendments 
are classified as substantial when they have a significant impact on the safety of the participants, 
on the scientific value of the study, on the conduction/ management of the study or on the quality 
and/ or safety of any IMP used in the study. If none of these criteria is met, the amendment is 
classified as non-substantial (27). 
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During the internship, I performed, with the other CRAs, the notification of non-substantial and 
substantial amendments to INFARMED and CEIC. For both tasks, I helped on the elaboration of 
the notification letter, in which the alterations performed as well as the reasons were explained. 
The substantial amendment represented a bigger obstacle because it required the comprehension 
of the Clinical Trial and the identification of the alterations performed because the Sponsor did not 
send an alterations track. In this amendment, new information regarding IMP’s pharmacokinetic 
enabled the alteration of the principal objective, the creation of a new study group, the increase of 
the sample size, the modification of eligibility criteria and of the study’s procedures. Due to these 
modifications a new version of the Protocol, of the IB’s, of the PIS and of ICF was created. The 
application submitted to CEIC and INFARMED included these new documents and a cover letter, 
in which the alterations were identified and explained.  
  
27 
3.3 Monitoring Activities 
Studies’ monitoring is a GCP and legal requirement (3, 8). This activity is important to assess the 
progress of the study at a specific centre and to ensure the complete adherence to the latest 
approved version of the Protocol/ Amendment(s), the quality of the data and the maintenance of 
the rights, safety and well-being of the participants. Also, the monitoring visits assess the 
compliance with ICH GCPs, relevant SOPs and applicable regulatory requirements. Monitors 
should also verify if the study data are in accordance with source documents and if each data is 
attributable to a real patient, legible, contemporary, original, accurate, complete, consistent 
enduring and available when necessary. Furthermore, the Monitors must be the link of 
communication between the Sponsor and the study’s centres and team (8). 
During the internship, DATAMEDICA performed monitoring activities mainly for oncology clinical 
studies and non-interventional studies. The Erro! A origem da referência não foi encontrada. shows 
the number of monitoring activities performed by me during the internship and the Table 2 
summarizes the specific tasks that I performed in each one of them. However, I did not had the 
opportunity to perform in-house monitoring activities nor to support study team in tasks such as 
IMP management, subjects’ recruitment, and procedures’ schedules. I’ve noticed from the work of 
my colleagues that it is really important to have a good documentation support to assure the 
efficient response to the study team’s questions. 
 
Figure 5. Number of monitoring activities performed during my internship 
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Table 2. Specific monitoring tasks developed by me during the internship 
Monitoring 
Activity 
Specific tasks performed/ assisted 
SIV 
 Protocol training. 
 Preparation of study presentations in the centre’s perspective. 
 Preparation and revision of Study Files: impression and archive of 
documents, missing documents identification. 
 Training in Sponsor’s SOPs. 
MV 
 Elaboration of documents designed for medication management by CRA in-
house, for MV scheduling and for study team’s support regarding visits and 
procedures.  
 Revision of Study Files: verify the presence of ICFs; assess document logs 
regarding precision, consistency, completeness; revision and collection of 
essential documents. 
 SDV of CRF. 
 Adverse Events (AEs) and Serious Adverse Events (SAEs) report revision. 
 Assessment of the need to perform a new training to the study’s team. 
 Verification if correction of findings of previous MVs were performed. 
 Actualisation of periodic status of the study. 
MV at 
Pharmacy 
 Revision of a Pharmacy File (PF): verification of shipping, receipt, 
temperature logs, drug accountability and destruction/ return 
documentation. 
 Revision with study team of the preparation and dispense procedures. 
Monitoring 
visits report 
 Support on the resolution of queries raised after report revision. 
COV 
 Revision of Study Files: impression and archive of documents, missing 
documents’ identification, verify the presence of CVs; assess document 
logs regarding precision, consistency, completeness; revision and collection 
of essential documents. 
 Medication accountability. 
 Preparation and schedule of medication return.  
 
In the following subsections, each monitoring activity mentioned before and the specific tasks 
related will be detailed. 
 
3.3.1 Co Monitoring Visits 
During my internship at DATAMEDICA, I had the opportunity to follow other DATAMEDICA’s CRAs 
in several monitoring visits to the study centres. I had the opportunity to be present at Site 
Monitoring Visits (SIVs), to help study responsible CRA in the conduction of periodic Monitoring 
Visits (MVs) and to attend a Close-Out Monitoring Visit (COV) to a centre that had not recruited any 
participants. In this chapter, I will describe the activities performed in this scope. 
Before any of the described activities, DATAMEDICA’s CRAs were trained (self-training or 
according with Sponsor requirements) in the Sponsor’s SOPs, in the Protocol and in the study’s 
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objectives. We also needed to be aware of the written ICF and of any other written information to 
be delivered to the participants (8). 
 
3.3.1.1 Site Initiation Visits 
The SIV is performed before patients’ recruitment and its main objective is to prepare the centre for 
study conduction. In some centres, it is possible to schedule a meeting with all the study team, 
however, due to schedules’ incompatibility, the CRA must go through all the Hospital Services 
involved in the study. I attended to a SIV that lasted two days due to the huge number of Hospital 
Services involved (medical oncology, cardiology, pharmacy, radiology, pathological anatomy, 
clinical laboratory, day hospital, and nursing) and it was not possible to coordinate a meeting with 
all the team members together. Therefore, the CRA needed to go to all the Hospital Services. In 
some centres, I have noticed a limited availability of health professionals in the scheduled visits. 
In other SIVs that I attend to, the centre was only considered open when the Principal Investigator 
(PI) received the Green Light Form, which is sent after an evaluation by the Sponsor of the 
capacity of the centre and the study team to conduct the study through assessment of 
documentation sent by the CRA, such as INFARMED, Ethics Committee and site Administration 
Board‘s approvals, signed Clinical Trial’s Agreement, CVs of the Investigators and of the Head of 
Laboratory, as well as Laboratory Certification, and other relevant documents. 
Besides CRA’s training, SIV’s preparation includes the development of a presentation (or the 
adaptation of a presentation sent by the Sponsor) and the creation of study files: Trial Master File 
(TMF), Investigator Study File (ISF) and Pharmacy File (PF) and revision of Essential 
Documentation, such as Financial Disclosure, CVs, Sources Data Report, Acknowledgment of 
Receipt (AoR) for Protocol and Investigator Brochure (IB), and Monitoring Log, assuring that all the 
relevant documents are well and accordingly archived. 
During the SIV, the Study’s Protocol must be reviewed and discussed with the study’s team, mainly 
focusing on eligibility criteria, study´s design and procedures. Training of study’s team should 
include the completion of the CRF and the procedures for reporting Adverse Events (AEs) and 
Serious Adverse Events (SAEs). Team responsibilities should also be discussed, especially PI’s, 
as well as the monitoring plan (28). Moreover, at the Pharmacy, the specifications concerning 
reception, storage, handling and return/ destruction of the medication sent by the Sponsor should 
be discussed. Furthermore, it is relevant to inform the study’s team regarding the other study 
centres that will be included, patient’s recruitment at the time in Portugal and, if applicable, in other 
countries. 
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3.3.1.2 Monitoring Visits  
Periodic Monitoring Visits (MV) are performed after patient’s recruitment at the centre and are 
scheduled as defined on the monitoring plan, which also specifies the percentage of SDV that 
should be done by the CRA at each MV. 
Before MV’s conduction is essential to prepare it. Basically, during the internship, I prepared 
monitoring visits by starting to identify what was done at the last visit. After the identification of 
which patients’ visits were previously monitored, I went to the CRF to verify which visits occurred 
since then and that must be monitored. Also, I go back to pending’s issues from last MV registered 
in the MV’s report and verify if they were already corrected. A checklist of outstanding issues that 
must be verified during MV is also prepared, to avoid forgetting any relevant points. 
Through the internship, I was able to witness an inadequate support from the Investigators at 
Hospitals regarding the MV. Besides the pharmacy, where the pharmacist helps the CRA during 
the visit, monitoring activities are also performed in the company of the Study Coordinator (SC) 
and, due to his/ hers limited availability, the Investigator only appears when it is absolutely 
necessary to add or change any information on patients’ clinical process or when it is necessary to 
sign any documents. Important tasks to the study conduction are also delegated to the SC, as the 
filing of the CRF. Therefore, SCs are important elements of the study team, in whom Investigators’ 
responsibilities are delegated and, in many occasions, are approached to clarify any issue from the 
protocol instead of Investigator. 
Source data is all the information necessary for the reconstruction and assessment of the Clinical 
Trial’s conduction and is recorded in original registers or through authenticated copies of the 
original ones, defined as source documents. SDV is a confirmation process that assesses if the 
data collected on the CRF correctly reflect the data registered at original documents defined at the 
SIV as source documents. These documents can be patient’s clinical process, laboratory results’ 
reports, patient’s diary, pharmacy’s registries, exams’ reports and, in some cases, CRF could be a 
source data document if the information is directly inserted on it. CRF as a source data is 
acceptable only if the information in question would not usually be entered as medical records in 
clinical practice, and if the knowledge of such information is not required by the Investigator or 
other health professional who concurrently/ subsequently treat the study’s participant (25, 29, 30). 
The extension of SDV is defined on the monitoring plan and depends on several factors, such as 
the phase of the Clinical Trial, the quantity of data, human resources and their availability, 
Investigator´s research experience, etc. One hundred per cent (100%) SDV could be a valid 
approach, mainly when the number of subjects at a trial centre is small and the CRA can verify all 
the data inserted on the CRF during a MV. However, when this approach is not feasible, it is 
important to define which is the critical information to the study and to the final results, namely 
primary efficacy endpoint, eligibility criteria, visits’ dates, adverse events, concomitant medication 
and medication dispense, retrieval and accountability (31). 
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There are two methodologies to perform a SDV: by direct verification, in which the monitors have 
direct access to patient’s clinical process; and by indirect verification, in which Investigator answers 
to the Monitor’s specific questions regarding patients’ data. CEIC allows the performance of SDV 
by a limited direct verification and the methodology to perform this verification is described at 
CEIC’s guide “Acesso aos dados do processo clínico dos participantes em ensaios clínicos pelos 
monitores” (30). 
Besides SDV, the monitor must review IF and PF during MVs in order to evaluate the documents 
and their archive. In the several MVs that I assisted, during the course of files’ revision, the most 
common findings observed were: missing CVs of study’s team or not updated after inclusion of new 
staff, insurance not updated and without validity date, originals documents’ archive instead of 
copies, missing Clinical Trial Agreement or Study’s Protocol versions, and so on.  
It must be reinforced during a MV that whenever the study team changes, the CRA must be 
informed, and the Investigator or SCs should be asked if it did.  
Besides SDV, I also performed medication’s accountability and destruction during MVs. Drug’s 
accountability is essential to monitor patients’ compliance with the study medication and to assure 
the integrity of the clinical data. Noncompliance compromises patients’ safety and affects the 
quality and acceptability of study’s results. Therefore, drug accountability is a requirement of GCP 
for any trial that uses study-supplied medication. Correct drug accountability includes the 
evaluation of drug reception, storage, handling, dispensing, administration and return. To allow this 
assessment to be completed and accurate records must be well archived. Also the return or 
disposal of unused medication must be correctly documented (32).  
Regarding the storage of study’s medication, the CRA must confirm if the storage is in a securely 
locked area with temperature/humidity control. Therefore, in MVs, CRAs should require access to 
temperature and humidity logs to verify if any drastic alteration of storage environment that could 
impact quality of medication occurred. During MVs, CRA also check the dispensing of medication, 
which has to be according to study protocol and can only be provided to study participants. Before 
drug’s return or disposal, counting of the used and unused medication is required to verify patients’ 
compliance. During the MVs, I performed drug’s accountability of pills and liquid ampoules and also 
performed the accountability verification made by the responsible to this task, who is normally the 
pharmacist. The documentation of all these processes is mandatory for the correct accountability 
and reconciliation of medication. Accurate records are essential to assure that medication was 
dispensed to the participants according to the study’s protocol, to verify patient’s compliance and 
data validity. 
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3.3.1.3 Close-Out Visits 
A Close-Out Visit (COV) is the last monitoring visit performed at the study’s centre. This visit aims 
to discuss with the Investigator the procedures that will follow the end of the study, to ensure that 
all activities required for centre close-out are performed and completed, that the copies of essential 
documents are correctly archived and that all study’s materials were collected from the centre and 
returned to the Sponsor (8). The correct archiving of documentation is essential because it makes 
documents accessible in the future if needed for regulatory reasons, allowing the Sponsor or the 
Competent Authorities to reconstruct the study at the centre and to assess if the study was 
conducted in accordance with the Study’s Protocol and with applicable laws and regulations. 
These visits normally occur when there are no participants being followed at the centre and when 
all the AEs/SAEs queries (data clarification) are resolved and completed. However, I assisted a 
COV of a centre that was conducted because study team have not recruited any study participant 
during the recruitment period. 
The COV must be confirmed with the Principal Investigator and the date and time and who will 
attend the meeting should be determined. In the COV that I attend, the PI was on maternity leave 
and her functions were delegated to a, therefore the meeting was only attended by the Sub-
Investigator and by the Pharmacy’s responsible.  
During the visit, the study materials, namely the CRF files, were collected to be sent to the Sponsor 
and the Investigator File (IF) was reviewed and checked to ensure the correct archiving of essential 
documents, such as delegation log and screening log, ICF, patients’ screening and enrolment log 
(which were not applicable at the COV that I attend to). During IF revision, duplicates and 
unnecessary copies should be removed, along as paper clips and staples, the index must be 
updated and note to files must be added if any section is not applicable or if documents are missing 
or wrongly archived in another file. Commonly, the IF must contain the original documents of the 
ICF, subjects’ log, visits’ log, follow-up letters and material and medication AoR. However, the last 
one could be archived at the PF. The originals of the signatures’ pages of study’s Protocol, CVs, 
laboratory certificates and delegation log must be collected and their copies must be archived. 
Nevertheless, each Sponsor must have is only requirements defined by SOPs, therefore, it is 
important to review Sponsor’s SOPs before each visit (8).  
It is also important to verify if all the AEs and SAEs were adequately reported, followed-up and 
documented. The discussion of the Final Study Report and publication plans and scheduling, along 
with the clarification of roles and responsibilities must also take place. 
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3.3.1.4 Monitoring Visit Reports 
After any type of MV, a report should be done as soon as possible, when the information is still 
clear and can easily be remembered. This time period is usually defined by Sponsor’s SOPs or, in 
their absence, by DATAMEDICA’s. DATAMEDICA has a monitoring visit report’s template to be 
used and the related SOP defines a 10 days period to the development and revision of the report. 
The report must identify the study, MV date, the centre in which the visit was conducted and the 
personnel that attended the visit. A brief resume of study status on the centre can be done, 
approaching target recruitment number, number of participants screened, recruited, completed and 
withdraw. The report must also addresses the following themes: Study’s Team (any change in the 
staff, new members’ training, functions’ delegation), Investigational Products (adequate storage, 
quantity, documentation of receipt, usage and return, expiry date, adequate dispense and correct 
use), CRF (accurately record data, consistent with source documents, correct documentation of 
concomitant medication, intercurrent illness, missing tests or examination, withdrawal situations), 
Protocol Deviations (ineligible participants’ inclusion, identification and report of protocol’s 
deviations), AEs (AEs and SAEs’ report) and Study Files (archive, maintenance, and essential 
documentation revision). 
After submission of the report at the platform, the document must be sent for Sponsor’s revision 
and, after this, questions can be raised to the CRA. When finished, the report is sent to the centre 
along with a follow-up letter that summarizes the visit and describes any critical findings or required 
action items. This letter should clearly identify all the significant findings, deviations, deficiencies, 
conclusions and outstanding issues to inform the study team and to help them to correct these 
issues. 
To standardize the report preparation in international CTs, in which there are several CRAs, 
Sponsors often choose to create an online platform. This tool also helps to control the report’s 
development and revision’s times. 
During the internship, I did not had the opportunity to develop a monitoring visit report since the 
beginning. However, after Sponsor’s revision, I have corrected the queries and answered all the 
raised questions. 
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3.4 Data Management 
Study’s data covers all the information collected during the study conduction and should reflect 
what have occurred on its course. The quality of the data depends on the study design, the 
selection and the quality of the measures and of the measurements devices, as well as the 
experience, training, competence, and motivation of the study team responsible for taking and 
recording the measurements, and on the choice and quality of data capture, processing, storage 
and analysis (33). Consequently, a good results’ analysis depends on the quality of the data. 
Clinical Data Management (DM) activities represent a critical phase in clinical research, with the 
main objective to generate high-quality, reliable, and statistically sound results. DM is the process 
that covers all the phases of study’s data collection, cleaning, and management DM activities 
include CRF design and annotation, database design, data entry, data validation, discrepancy 
management, data coding, data extraction, and database locking (34). 
Before analysis, the quality of data should be assessed and the information contained must be 
changed into a format that are readily analysed and interpreted. The data must be accurate, which 
means that there are a correspondence between the collected data and the real values of the 
“phenomena” that is being measured; precise, which reflects the degree of detail of study’s data; 
consistent, considering the level of concordance between real data and the data present at the 
database; complete, which expresses the rate of missing values at the database; and data must 
have integrity, that corresponds to data usability and soundness, characteristics that are influenced 
by data´s validity and completeness (33). 
It is not possible to compare DM activities performed at DATAMEDICA in the scope of clinical 
studies performed within national territory and DM activities performed at a pharmaceutical industry 
or performed by a subcontracted entity in the scope of a multinational Clinical Study. Regarding the 
last ones, before collecting worldwide information and pool it together, data managers must take 
into account variability regarding culture and religion, medical practice, laboratory standards and 
units, classifications disease and standard treatment , drug’s reactions, self-medication, drug’s 
interactions to conceive a complete DM Plan (25). 
A DM Plan should include a data origin flowchart, project’s team list and the respective 
responsibilities, CRFs log-in sheet (that makes the correspondence between user log-in and 
investigator), data query sheet, audit sheet and results’ documentation and a sample document for 
formal notification of database’s closure. To create this document is necessary to have access to 
the protocol, CRF, relevant literature, log-in and tracking methods, file structures, codification rules, 
query handling procedures, required edition checklist, laboratory normal ranges and units, clinically 
significant ranges, timelines, quality control rules, error analysis and criteria to release and close-
out the database (25). 
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The DM activities performed at DATAMEDICA during my internship, consisted on CRFs’ design, 
databases’ design, data entry, data coding, and databases’ revision and locking. However, I did not 
had the opportunity to work with any DM software tool, also known as Clinical Data Management 
System (CDMS). Due to this, an audit trail of the data, which is a chronological record that 
documents a sequence of activities performed since initial data recording until data locking, was 
difficult to maintain and control. Audit control is an important tool, mainly for studies that are 
conducted during a long period or in which the study team changes frequently. 
A CRF is a data collection tool, printed or electronic, used in clinical studies that support the record 
of all protocol-required information (8). The design of a CRF influences data collection, data entry 
and validation process as well as data management and statistical analysis. The characteristics of 
a well-designed CRF are that the CRF should be informative, structured and simple, and should 
allow the collection of legible, consistent, and valid data, with the aim to decrease the time to 
perform both the data entry and query generation and resolution. Therefore, data must be 
organized in a format that facilitates and simplifies filing of the blank spaces and posterior data 
management and analysis. Furthermore, the collection of unnecessary information and large 
amount of data should be avoid because it will result in wasted resources. 
A CRF must have headers and footers with elements that identify the Sponsor, the Study’s 
Protocol, the visit and the subject in question, CRF version and date, and page identification/ 
numbers. These informative features provide a brief description of the study and the schedule of 
assessments allowing the identification of the correct CRF, preventing the use of an incorrect page 
or version (35). 
When designing CRF layout, it is important to focus on the user, on the one who will perform data 
entry, and classify the data regarding time dependence. Information collected at a specific moment 
in time is called Non-time dependent data, such as demographics information and medical history. 
Time-dependent data is information recorded repeatedly over the study, such as vital signs 
collected at several study visits. Information collected over the study but not related to a specific 
visit is cumulative data and adverse events and concomitant medications are good examples. 
Usually, non-time dependent and time-dependent data are recorded in per visits pages of the CRF 
and cumulative data is recorded in cumulative logs, in which specific pages are structured just for 
this information (36). 
DATAMEDICA has developed printed CRFs and, along with outsourced programmers, electronic 
CRFs. Both approaches have pros and cons. Paper CRFs are a better option for small studies. 
However, electronic forms are favourable because they are less time-consuming, while reducing 
the probability of entry errors. Also, audit trail of the data is easily performed and repetitive data, 
such as study identification, participant number or visit number, can be generated automatically by 
the system. Electronic CRFs allow the connection of different pages of the CRF and prior definition 
of data validation rules, which are useful tools during database cleaning performed along the study 
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duration, and did not require data entry because it allows the data’s automatic exportation to an 
informatics application previously defined, avoiding data entry errors. Regarding data cleaning, the 
activities may be performed during study conduction, which reduces query resolution’s time due to 
a faster communication between the data manager, the monitor and the study’s team as well as 
timely database lock. Also, electronic CRFs enable the performance of in-house monitoring, in 
which the CRA verify data outside the study’s site. Yet, electronic CRFs require adequate and 
available on-site technology, training and motivation of study’s team, maintenance of the software 
and a higher investment.  
In summary, CRF’s development is a process that must end with a simple form or with a set of 
forms. During the internship, I had the opportunity to create paper CRFs and documents that 
supported electronic CRFs’ development. However, I did not had the chance to accompany the 
electronic CRF’s development along with the informatics as well as its validation. To keep the form 
simple and still collect all the required information is a complex task, as well as the comprehension 
and identification of potential connections between electronic CRF pages. 
Data entry is a relevant step between data collection and database cleaning and statistical 
analysis. The introduction of information in the database is a time consuming activity and requires 
many human resources when the Clients want to entry a large quantity of data in a limited time 
period. At the internship, during the data entry of paper CRFs, it was possible to detect some 
relevant points that I have taken into account during subsequent CRFs’ design:  
 Use of consistent formats and font style and size;  
 Use of clear and concise questions and instructions;  
 Use of visual clues that indicate place and format of the data to be recorded;  
 Use of check boxes whenever appropriate;  
 Use of thick lines to indicate where to enter the answer and to separate columns;  
 Give detailed guidance in bold or italicised;  
 Minimise free text answers and use precoded answers, such as yes/ no, male/ female, 
severity of AEs, administration mode, etc.;  
 Specify the unit of measurement and indicate the number of decimal places required;  
 Use standard format throughout the CRF, such as data format. 
The revision of a database includes the identification of missing CRF pages, missing visits or 
missing values, the confirmation that the screening/ randomisation numbers are given sequentially; 
the evaluation if all the blanks spaces are properly filled; the clarification of all text items, such as 
adverse events, concomitant medications, physical examinations, ECG and others; the verification 
of drug’s dispense and return (25). 
Database’s cleaning aims both to identify the errors that occurred during data collection and data 
entry and to correct them or minimize their impact on study’s results. Due to the great impact of 
data handling on the data quality and study results, database cleaning is an important task, 
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however, it receives less attention in GCPs and in Data Management Guidelines. There are gaps 
of knowledge about good methodologies and standards to apply in this activity, important to 
separate data editing from data manipulation. Some useful techniques for data cleaning are 
statistical outlier’s detection and handling of missing data. However, little focus has been given to 
the treatment of missing data (37). During the internship, I helped the biostatistician performing 
database cleaning of a 6-year study that included more than 1.300 patients. Due to access 
constraints to CRF online platform and to the handover of several study’s CRAs, some data were 
missing and some data disparities were find. Besides the access to partial source documents, not 
all the missing values were completed, which has reduced the quality of the data. 
Some missing values were related to the alteration of CRF’s baseline form after the recruitment 
period has closed. Site’s study team were not correctly updated by the study’s monitor and was 
induced in error by the information of completeness status of the form which did not reflected 
CRF’s alteration. Therefore, the new data were not introduced in the CRF. In this particular study, 
an audit trail was essential to really understand the conduction of the study and all the alterations 
and measures implemented.   
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3.5 Advisory Boards 
An advisory board is a meeting aimed to achieve a non-binding consensus regarding a specific 
topic. These meetings should be performed in a neutral space and/ or in an informal environment 
(like a hotel room), once that allows a much more free expression of opinions, giving more flexibility 
to the structure and management of the event. It is important to point out that advisory boards do 
not have the authority to create legal binding decisions, and, therefore, are mainly instructive. 
First, when planning an advisory board, a clear and well-defined purpose should be established, 
with the final purpose to attain fully developed opinions and valuable recommendations. This 
purpose must be based on clinical needs. Second, the right experts should be invited. The 
selection of the experts should take into account their education, training and experience on the 
topic that is being discussed. Also, the group of experts must be representative, in order to capture 
all the spectrum of opinions. The meeting’s moderator must be capable of impartially conduct the 
group on the discussion theme, controlling each argumentation time and moving forward towards 
the objective, aiming to enhance effectiveness. Moreover, before the advisory board, a meeting 
agenda describing the points that will be discussed should be prepared and sent to all the 
participants, also aiming at achieving the predetermined purpose. The presentations to guide the 
meeting must be didactic and adequate to the education level of the experts, to the theme and to 
the time available (38). 
Besides the logistic part, advisory boards or expert panels or consensus meetings must be 
implemented in compliance with “Code of Ethics for Promotion Practices of the Pharmaceutical 
Industry and Interaction with Health Care Professionals and Institutions, Organizations or 
Associations Comprising Health Care Professionals” of APIFARMA (Associação Portuguesa da 
Indústria Farmacêutica). 
Meetings with health professionals are essential for the development and improvement of health 
care, new medicines and technologies. Once there is a possibility of influenced decisions the 
conduction of the meeting should be the most objective possible so that bias can be avoided. For 
this purpose, APIFARMA developed the Code of Ethics previously mentioned. Chapter three 
defines the requirements to conduct promotional, scientific and educational venues regarding event 
venue and hospitality. In all events supported by DATAMEDICA, the venue was adequate and the 
meetings was not a place with leisure, entertainment or sport purposes. The hospitality provided by 
the Client was limited to travel, meals and registration costs (39). 
DATAMEDICA was hired to support and assist in the organization of two advisory boards about 
multiple sclerosis and performed the corresponding reports. In these reports, all the items 
discussed, all the opinions stated and all the disagreement points were thoroughly described. 
I took part in one of these advisory boards and, before the meeting, a self-training on the disease 
(multiple sclerosis) and available treatments has proved to be quite important. This autonomous 
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study was critical to follow and understand the experts’ discussion on the theme. In this project, I 
was responsible to: 
 Collect relevant information regarding multiple sclerosis prior to the meeting,  
 Attend to the advisory board and,  
 Prepare the report.  
The preparation of this report turned out to be very challenging due to the specificity of the theme. 
The audio recording of the advisory board turned out to be very useful for this activity. Even though 
it did not had a great audio quality, the main points discussed and the main ideas raised during the 
meeting were possible to extract. 
Besides attending to one of the above mentioned advisory boards, I had also the opportunity to 
participate in a consensus meeting, where health professionals and others were consulted as 
experts. This one differed from the first ones because its main objective was to obtain a consensual 
information of an expert group to support investigational projects. During the internship, I assisted 
three expert’s panels that were conducted to determine the most accurate and similar to reality 
data regarding clinical and budget inputs for pharmacoeconomic models, which were focused on 
cervical cancer screening strategies. In the next section, more information related to this project will 
be given. 
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3.6 Pharmacoeconomic Studies 
Pharmacoeconomic study is an analytical tool used frequently to support the decision of financing 
and management of pharmaceutical medicines or health technologies by the health care system. 
Therefore, cost-benefit, cost-effectiveness, cost-minimisation, cost-utility and cost-of-illness 
analyses are useful to compare the pros and cons of different strategies, such as medicines, 
technologies or medical practices/ interventions. These evaluations allow generating valuable 
evidence that support the selection of the optimal allocation of limited resources (40). 
Pharmacoeconomic appraisals may be performed regarding several types of technologies, such as 
medicinal products, medical devices, diagnostic techniques, screening tools, surgical procedures, 
therapeutic technologies or systems of care (41). 
 
Table 3. Summary of the most relevant pharmacoeconomic studies (42) 
Pharmacoeconomic Studies 
Cost-Benefit Analysis 
Comparison of costs and benefits of two or more interventions. 
Outcomes are measured in monetary terms. 
Cost-Effectiveness 
Analysis (CEA) 
Comparison of costs and outcomes of two or more interventions.  
Cost-Minimisation 
Analysis 
Comparison of costs of interventions that provide the same outcome. 
Cost-Utility Analysis 
Comparison of the cost per Quality-Adjusted Life Year (QALY) for two 
or more interventions that provide diverse outcomes. 
Budget Impact Analysis 
(BIA) 
Evaluation of the expected alterations in the expenditure of a health 
care system after the adoption of a new intervention. 
Cost-of-Illness Analysis Analysis of the costs of a disease 
 
Pharmacoeconomic analysis can be divided in three phases: 
 Scoping phase, in which the specific question to address is defined and the suitability of 
the analysis proposed is appraised. Also, critical issues are determined, such as target 
population and comparators. 
 Assessment phase, which comprises a bibliographic revision of clinical evidence and an 
economic evaluation of the technology. 
 Appraisal phase, the pharmacoeconomic analysis. 
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The design and performance of pharmacoeconomic studies may vary regarding the methodology 
used, even having the same economic basis. Therefore, in this report, the methodologies adopted 
by DATAMEDICA will be introduced. 
During my internship DATAMEDICA performed two pharmacoeconomic analyses: Cost-
Effectiveness Analysis (CEA) and Budget Impact Analysis (BIA), with the main objective to decide 
which screening strategy of cervical cancer was more cost-effective or had less budget impact. To 
perform these analyses, electronic models that focused on the disease in question and on different 
screening strategies were created. Also, several key features were defined during model setup:  
 Choice of comparator(s). Medical practice was one of the strategies selected. However, 
the model also included other strategies defined by Portuguese Society of Gynaecology;  
 Target population (age range, specific country or region, ...); 
 Analysis perspective. Regarding INFARMED methodological guidelines and NICE guide 
documents, the perspective is the viewpoint from which the economic evaluation is 
performed. The most correct perspective is society perspective that covers the patient, his 
family, health professionals and payer entities (public or private); 
 Time horizon, that should be sufficiently long to reflect all the potentially important 
differences between the technologies regarding health outcomes and costs (41, 42). 
Clinical and costs inputs were not defined during model setup. Clinical inputs included 
epidemiologic data related to the disease, such as incidence, prevalence and progression/ 
regression of disease probabilities, and information related to the screening strategy (specificity 
and sensitivity). In this scope, costs inputs comprised office visits’ costs, screening and diagnostic 
exams prices, and treatments expenditures. 
Model inputs were validated by an expert panel, in which I participated, and included Clinical Trials’ 
published data, published literature data, and data on file. For the success of the expert panel, a 
bibliographic revision was performed and a survey that summarised all the clinical data relevant as 
model inputs was developed. For this survey, I had to collect several data regarding clinical results 
of Clinical Studies and resume it in a tabular format for an easier comprehension and analysis.  
During the expert panel, the relevant strategies to compare on the pharmacoeconomic analysis 
and the clinical and costs inputs to introduce on the model were discussed. A report to summarise 
the expert panel’s conclusions was developed and the model was updated with the inputs 
discussed. The expert panel and the pharmacoeconomic analysis involving the mathematical 
models’ results were aimed to scientific public release in a complex publication plan that will be 
mentioned in section 3.7 Medical Writing. However, it is important to specify the difference between 
both the communications (abstract or article). The model set-up was changed regarding start age 
for screening (at 25 or at 30 years old), screened population (Portuguese or a specific Portuguese 
region), different screening strategies in comparison, and colposcopy exams after the screening 
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execution (or not). Due to these variations, several comparisons and analysis were possible to 
perform and to divulgate to the scientific community. 
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3.7 Medical Writing 
Medical writing is a transversal activity of Clinical Research that includes documents conception, 
management, review, approval and release. The activities developed by a Medical Writer are 
extremely important to the projects and to the company because their success depends on proper 
documentation of research plans and results release and on all the written records that supports 
them at any period (43). 
Medical writing services include Clinical Research and Publication support. The first one comprises 
all the MW activities, such as the creation, translation or adaptation and revision of Study 
Protocols, Patient Informed Consents, Nurse Sheets, Cover Letters, Investigator Brochure and so 
one. It also includes the conception of Clinical Study Reports, which are developed according to 
ICH E3 “Structure and Content of Clinical Study Reports”. It also includes the establishment of 
documentation quality management system-related which is important to assure an efficient work 
of the DATAMEDICA’s team, namely Quality Manual, Standard Operating Procedures (SOPs) and 
Monitoring Plans. Publication support is a service directed to the conception of diverse publication 
forms: scientific journal articles, abstracts for conferences’ submission, poster presentations and 
oral communications. Medical writing also gives support at the revision, bibliographies, citations or 
references’ management, and at the adaptation of the documents’ format according to specific 
directives. 
During the internship, I had the opportunity to perform the following medical writing activities: 
 Literature reviews; 
 Development of Study Protocols, Patient Informed Consents, Nurse Sheets, Cover Letters; 
 Conception of abstracts for Congresses’ submission and, after approval, the related poster; 
 Development of articles for submission to national and international journals; 
 Support DATAMEDICA’s Financial and Administrative Department creating the budget 
proposals according to Clients’ requests or as a result of a Scientific Department 
brainstorming aimed to meet Clients’ needs. 
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Figure 6. Number of MW activities performed during the internship 
 
Literature revision is important to support a new Clinical Study and all the related documentation 
and equally to support a DATAMEDICA’s service proposals for a new business opportunity. The 
attainment of theoretical knowledge is of a great importance to guarantee that DATAMEDICA’s 
services met clients’ requirements and main objectives. 
Literature revision in DATAMEDICA is mainly performed through Pubmed Database and Clinical 
Trials Database (clinicaltrials.gov and clinicaltrialsregister.eu). Besides published review articles 
that give an overview on the theme, we also search for published clinical studies, undergoing 
Clinical Studies and authorities releases.  
At services proposal development, literature revision is important to support the service to be 
provided and to justify the methodology that DATAMEDICA advocates. It is important to convince 
the client to allow DATAMEDICA to be responsible for the service needed. The implementation of 
team discussions and brainstorming meetings after bibliographic research and self-training on the 
theme is a good way to define the best methodology to accomplish a specific service or to achieve 
a certain result or to reach predefine objectives. During the internship, I had the opportunity to write 
budget proposals in diverse fields of Clinical Research, such as Clinical Studies, 
Pharmacovigilance, Medical Writing and Quality Management System, and also to participate in 
discussions over the methodologies that will be presented to the Client. This activity allowed me to 
understand the budget calculation process performed at DATAMEDICA.  
Additionally, DATAMEDICA had MW activities that I was able to assist, support and perform by 
myself during. The most challenge one was the creation and revision of CT Protocols. Regarding 
Clinical Studies, table 4 summarizes the most relevant elements that should be address in a 
Protocol.  
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Table 4. Most relevant items to address in a Study Protocol and brief description of each one (8, 22) 
Protocol items Brief description 
Administrative Information 
Study title and code 
Descriptive title and code, which allow to identify study design, population and 
methodology. 
Roles, contacts and 
responsibilities 
Names, affiliations, contact information and roles of Sponsor and Protocol 
contributors, such as Medical Coordinator, Biostatistics, CRO (if applicable). Name 
and contacts information of Coordinator Investigator, Monitor Responsible and 
Sponsor’s Medical Expert. 
Composition, roles and responsibilities of any committee defined to the study (if 
applicable). 
Introduction 
Background, 
rationale and 
objectives 
Description of the research objective and the justification for the conduction of the 
study. 
Summary of relevant clinical and non-clinical studies and evaluation of benefits and 
risks due to the intervention. Explanation for choice of comparators (if applicable). 
Trial design 
Description of study design including study groups, type of trial (parallel, crossover, 
single group,...), allocation rate, framework (superiority, equivalence, non-inferiority, 
exploratory) (if applicable), study duration, participants eligibility and withdrawal 
criteria, study outcomes.  
Use of schematic diagram to explain the study design. 
Sample size 
Estimated number of participants that should be enrolled to achieve study 
objectives. Clinical and statistical assumptions that supported the sample size 
calculation. 
Study intervention(s) 
(if applicable) 
Interventions for each study group. Description of the study intervention(s) and the 
dosage and dosage regimen. Criteria for discounting or modifying allocated 
interventions for a specific participant. Concomitant medication or care allowed and 
prohibited. 
Data Management and Statistics 
Data collection 
methods 
The identification of any data to be recorded directly on the CRFs. Methods for data 
collection and any related process to enhance data quality. Description of used 
tools (questionnaires, laboratory tests,...) and their reliability and validity (if 
applicable). 
DM & Statistical 
analysis 
Plans for data entry, coding, security and storage. Definition of analysis population. 
Statistical methods to handle missing data. Statistical methods to analyse primary 
and secondary outcomes. Subgroup’s analyses. Timing of interim analysis. 
Ethics and Publication Considerations 
Description of ethical considerations relating to the project. Plans to maintain and protect personal 
information. Person/ entity which will have access to the final trial database. Financial and other competing 
interests of the different stakeholders. Plans for communication of study results. 
 
The creation of a Study Protocol should involve a multidisciplinary team work with qualified 
individuals such as physicians, Clinical Research methodology experts, biostatisticians, medical 
writers. As mentioned before, the Protocol must contain all the relevant information about the study 
in a simple and easily understandable way. The Protocol must maintain consistence in the entire 
document. I had the opportunity to review a complex Protocol generated by the Client, which had 
repeated information in an excessive way. This has difficult the document’s revision process. Also, 
during the revision, several questions were raised to the Client due to initial discrepancies 
contained within the document. 
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When developing long documents, such as Study Protocols or Manuals, there are important tools 
that facilitate the writing, reading and understanding of the document such as cross-references, 
automatic numeration, table of contents, glossary of non-standard or ambiguous terms and a list of 
abbreviations and references. These tools also help the document’s revision process, which must 
assess scientific accuracy, grammar, style inconsistencies, lack of clarity and other errors, as 
mentioned before.  
After development of the Study Protocol, it is possibly to start the conception of Informed Consent 
Form (ICF) and other necessary documentation. 
The ICF is the most important document for the protection of human subjects during their 
participation on clinical studies because it gives information regarding subjects’ rights and duties, 
as well as possible risks and foreseeable adverse events. During the trial, the ICF also protects the 
Sponsor from legal consequences if the patient is harmed in any way.  
The ICF consists of two documents: the Information Sheet and the Consent Form. Usually, they 
are considered as a pair of documents and not as separate ones. During the creation of an ICF, the 
following information should be included (8): 
 Explanation that the Clinical Study is part of a research and describe its purposes; 
 Treatment during the trial and the possibility for the occurrence of a randomised allocation 
to a study group; 
 Study design and procedures that will be followed; 
 Rights and duties of the participants; 
  Experimental aspects of the trial; 
 Expected risks for the participants as well as for embryo, foetus and nursed infants, and 
expected benefits of study participation; 
 Alternative treatments for the participant and their side effects; 
 Compensation and insurances for the participant if harmed; 
 Voluntary participation and possibilities for refusal at any time; 
 Open access to medical documents to the responsible monitors, auditors, Ethics 
Committees, Health Authorities; 
 Data protection and confidentiality; 
 Contact person/ entity in case of harm; 
 Circumstances and reasons that can stop the participation or the study; 
 Expected duration of subject participation; 
 Approximate number of participants that will be included. 
The ICF must be written in an understandable way to the subject and therefore, technical and 
medical jargon should not be used. The Consent Form must be signed and dated by the subject 
and by a person of the study team in the centre before any  participation in the study (8). 
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Besides the development of study documents, DATAMEDICA also supported the preparation of 
articles, abstracts, posters and oral communications. During the establishment of key points to 
address in each document, it is necessary to obtain proper acknowledgment about the theme and 
proper input from the authors. I supported the preparation of a revision article, without a proper 
input from the Client/ Sponsor, once the manuscript objectives hadn’t been previously defined. In 
other situation that I witnessed, the document was created, reviewed and changed without Client’s 
input or consent. These entropies delays the development process and following submission, 
which would not happen if specific deadlines, communication and follow up meetings exist. 
Abstracts creation process requires a good ability to synthesize. Each congress/ meeting has its 
own submission guidelines, specifying all the information that must be clearly stated, the number of 
words/ characters, and other relevant instructions. Abstracts main topics are: objectives, methods, 
results and conclusion. However, other topics could be required such as introduction and 
discussion. Regarding all of these sections, objectives, methods and results should receive greater 
emphasis, because these are the topics that explain what kind of research is being submitted.  
During the internship, I prepared an abstract, in which the results of the BIA were displayed: 
“Impacto Clínico e Económico de Diversas Estratégias para o Rastreio do Cancro do Colo do 
Útero”. This abstract was accepted for poster presentation at the “181ª Reunião da Sociedade 
Portuguesa de Ginecologia” and received the best poster award. After this one, other abstract 
created by me was submitted to the “13º Congresso Português de Ginecologia” and it was 
accepted for oral communication. At the moment of the delivery of this report, a third abstract was 
submitted and accepted also for oral communication to the 30th International Papillomavirus 
Conference (HPV 2015). Usually, the submission process of an abstract is an easy task because 
the submission guidelines are very clear.  
Posters’ development start after receiving the confirmation of the acceptance of the abstract to be 
present as a poster at the Congress. At DATAMEDICA, posters are designed using PowerPoint 
and the first step is the definition of the correct proportions of the PowerPoint slide that must be 
according to the Congress’s specifications, which is important to maintain the correct definition 
when saving the document as PDF. Simple fonts, such as Arial or Times New Roman, are of easily 
reading. When inserting images is important to assess its quality to make sure that they will not 
pixilated when impress. Others design features important to give a good appearance to the poster 
are the alignment of text boxes, pictures or graphs and the maintenance of a consistent spacing 
between sections and columns. 
Posters are a helpful tool to simplify the rapid communication of a research to national or 
international population. However, it does not substitute an article publication, which is essential to 
specify all the relevant details of methodology and to discuss and explain the results in detail.  
An article preparation is a more complicated process. The article must be correctly written to 
effectively communicate the research’s data, information and underlying message. To achieve that, 
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it is advisable to use a simple, concise and specific title that correctly describes the content; avoid 
complicated jargon’s use or a highly specialized language to experts of the area; exclude 
unnecessary details; avoid very long paragraphs and sentences and to use current literature (44).  
During the internship, I supported an article development without knowing the target journal to 
publish and also an article development for a specific scientific journal. At the first case, the 
conception did not take into account any instructions. For the second one, the instructions for the 
preparation of a manuscript to submit at the Journal of Lower Genital Tract Disease were taken into 
account. Besides relevant ethic’s considerations, this guideline defines word count limits, article’s 
structure, references’ format and other relevant specifications that help the Medical Writer in his 
chore (45). 
Article’s submission process is much more complicated than abstract’s submission. The process of 
submission to the Journal of Lower Genital Tract Disease started two months before the delivery of 
this report and, at the moment, is still pending. The main obstacles are related to the collection of 
all the necessary documents to submit (Disclosure Form, Copyrights, Cover Letters, Submission 
Checklists, …) from the authors, as well as its correct filing. 
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3.8 Quality Management System  
At the time of the beginning of my internship, DATAMEDICA’s QMS was under an extensive 
revision process headed by a QA Manager specialist. Even not being the focus of my internship, I 
helped in the revision of DATAMEDICA’s QMS.  
According to ASQ Glossary, a Quality Management System (QMS) is a “formalized system that 
documents the structure, responsibilities and procedures required to achieve effective quality 
management” (46). Therefore, the QMS is a set of processes, procedures and policies necessary 
for the planning and execution of the diverse activities of an organisation. In Clinical Research, the 
QMS is a requirement for all Good Practices activities because it assures, in an efficient way, the 
compliance with regulatory requirements and standards, and allows the company to accomplish 
Client expectations, which gives the company a competitive advantage (47). Furthermore, an 
effective QMS allows process control improvement, wastes and costs reduction, as well as 
increase the profit and the company’s market share. Furthermore, it involves all the collaborators 
and company’s Management and facilitates staff training. 
The QMS certification states that the products/ services delivered to the Client, are compliant with 
the relevant national and international regulations and standards, as well as the processes and the 
systems that support products/ services development. Certification is also an assurance to the 
target market and to the Clients all over the world. The certification of a QMS is assessed regarding 
“Quality Management Systems Requirements – ISO 9001:2008”. 
International Organisation for Standardization (ISO) is an independent, non-governmental 
organisation that develops international standard documents. Standard documents are made by 
experts of the area/ sector, through a consensus process (48). The implementation of ISO 9001 
allows company’s continuous improvement regarding mainly the QMS and processes and 
increases the capacity to deliver services that meet customer requirements and expectations. An 
efficient QMS enhance company’s profitability and demonstrate the commitment to the service 
quality. 
ISO 9001:2008 is based on eight quality management principles: 
 Customer focus 
 Leadership 
 Involvement of people 
 Process approach 
 System approach 
 Continual improvement 
 Fact-based decision making, and 
 Mutually beneficial supplier relationships 
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ISO 9001:2008 recommends a process approach. A process is any activity or a set of activities that 
use resources to transform specific inputs into specific outputs (46, 47). Process approach covers 
the identification and the systematic management of the processes allowing both the uniformity of 
tasks and their success. It also allows to easily identify which part of the process can be changed in 
order to improve its results. In this model, Clients are responsible to define the inputs requirements. 
Customers’ satisfaction assessment and validation is essential for the continuous improvement of 
the QMS and of the Company. To sum it up, besides providing the product/ service to the Client, 
the QMS must address measurement analysis, continuous improvement and resources 
management. 
“Quality Management Systems Requirements – ISO 9001:2008” defines six mandatory processes 
that must be documented as part of the company’s QMS: 
 Control of documents and records; 
 Internal audits; 
 Control of non-conformities; 
 Corrective actions; 
 Preventive actions (49). 
Quality implementation and improvement requires a very close involvement of company’s 
management regarding support and responsibility because this backing facilitates the involvement 
of the rest of the collaborators and allows us to have access to the resources needed in this 
process. However, at DATAMEDICA, QMS revision process could have been easier if 
DATAMEDICA’s management involvement had been larger, which was inconsistent with the fact 
that QMS revision was a strategic decision of the company’s Management, in order to define its 
objectives and continuously improve the services provided. 
During the internship, I supported the Quality Management System in the revision of the company’s 
organisational chart, which is a diagram that resumes the organisation structure, the relationships 
and the hierarchical positions of its departments and units. This diagram is important for the 
company because it allows to visualise the complete organisation of the Company. Due to the 
small size of DATAMEDICA, it was only structured a completed organisation diagram. The split of 
the cart in smaller charts for separate company’s department occurs when the company is larger 
than DATAMEDICA. For this task, it was required to understand company’s structure and the 
actual relationships between collaborators. At the top of the organisational chart, it is displayed the 
company’s Administration Board, below which we can find other hierarchical positions. Lines 
indicate the relationships within the company and dashed lines indicate relationships with external 
suppliers or collaborators. However, organisational charts also have limitations once they do not 
provide information about the managerial style adopted by the company and they do not show all 
the relationships developed with and by the company, it only shows formal relations.  
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I also started to perform DATAMEDICA’s Standard Operating Procedures (SOPs) revision. A SOP 
is a set of written instructions that guide a routine activity performed at the organisation. Therefore, 
SOPs provide the collaborators with the essential information to correctly perform each activity and, 
also, facilitate consistency in quality and efficiency of a service, even when occurs temporary or 
permanent personnel changes, while assuring compliance with organisational and legal 
requirements. Due to these reasons, SOPs are an integral part of a successful QMS. Besides 
detailing the work processes, they define responsibilities and timelines which are essential for the 
conduction of any activity, also stating the personnel qualifications necessary to perform the activity 
in question. SOPs success are influenced by their written quality and by the enforcement given by 
company’s management to reinforce the importance of following SOPs. 
To facilitate SOPs reading, they should be written in a concise and step-by-step format, using 
unambiguous and explicit information. Active voice and present verbal tense are recommended. 
The documents should be simple and short. Redundancy and overly length should be avoided. To 
illustrate the process, a flowchart is always a good choice (50). 
The revision of area-specific SOPs is being performed by DATAMEDICA’s collaborators 
responsible for the process because they are true experts, who actually perform the work or use 
the process. Therefore, they are the most capable to detail the process in such way that someone 
with limited knowledge or experience can successfully perform each task. The revision of Training 
SOP was delegated to me.  
I did not performed a simple revision because it was necessary to adequate the SOP’s scope to all 
the DATAMEDICA’s departments/ units, increasing the old scope that was only focused on CRA’s 
training. Besides a checklist that identify the essential training to give to a new collaborator or to 
refresh old ones, the documentation of the training must be performed and correctly archived. In 
clinical research field, adequate training in the Declaration of Helsinki, ICH GCP, European 
directives and regulations and national laws related to clinical studies are required. Additionally, 
DATAMEDICA’s collaborators must be trained at the company’s internal procedures. More specific 
training was adjusted according to the work position. For example, CRAs must perform protocol-
specific and protocol-related training.  
SOPs revision and adaptation process allowed me to exercise my knowledge regarding quality and 
my writing skills, while improving the efficiency of Company’s procedures and the quality of 
services.  
During the internship, I watched some faults that were committed due to the lack of an efficient 
QMS. One was the printing of the most recent budget proposals saved on DATAMEDICA’s server 
to deliver to the Client. However, that was not the most recent document and it did not have the 
costs of the proposed services. The error was only noticed during the meeting with the Client. The 
corrected document was not saved on DATAMEDICA’s server. It was archived only as an annex of 
emails exchanged within DATAMEDICA.
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4. DISCUSSION 
The next section will be a brief discussion of the relevant aspects of this training period, where the 
problems and challenges that I went through will be presented as well as all the positive and 
negative aspects identified. Therefore, I will make a reflection of the seven-month experience. 
This internship was a very rich experience and in this report I try to describe all the projects and 
experiences in which I was engaged. Even showing the big amount of knowledge acquired during 
the internship, I cannot properly show in this the report all the effort given and that I put in all the 
activities performed. Several projects required extensive hard work and availability to perform 
additional off-work hours due to the difficulty of the activities or due to the tight timelines defined by 
the Client. However, it was always part of my learning process and I am grateful for the opportunity 
that was given to me and to the colleagues that have guide me during these 7 months with wisdom 
and patience. 
I decided to perform my internship at a CRO because I believed that working for this stakeholder 
would be more beneficial to me. A CRO performs numerous services focused in all Clinical 
Research phases. As a small company DATAMEDICA was able to overcome my expectations 
because it was possible to learn and perform activities related to several Clinical Research areas. 
Therefore, besides the CRA focus of the internship, I gained experience in clinical studies 
conceptualization and development, pharmacoeconomic studies, data management, biostatistics, 
medical writing and QA. 
As it is possible to understand through the reading of this report, my internship was not focused on 
a specific activity. Instead, I performed activities in all the areas in which DATAMEDICA had 
projects. This lead to a more enriching experience because the amount of knowledge collected was 
huge and the necessity to improve my soft and hard skills was higher, challenging me to always do 
better and pursuit higher results. 
I am very fortunate to be involved in all the DATAMEDICA’s projects once that allowed me to 
comprehend that I do not see myself as a CRA. Before the internship has started, I really wanted to 
perform CRA functions, however the idea that I have changed and I realize that this was not what I 
want to do in the future. I thought that CRA position was stimulating and also allowed to travel 
between many different sites and places, to know different people and that I would like to be out of 
the office instead of being bored if staying at the office all the time. Yet, I recognised that CRA 
activities are not so appealing.  
Regarding the variety of activities performed during the internship, I was capable to see and act in 
different areas and I am now able to decide which activities I liked the most and that I would like to 
keep doing in the future. Nevertheless, this internship still leave me with the question of which 
activity I like the most, either to be involved in conception and development, or medical writing or 
QA activities. The first two are very stimulating and require continuous training and individual 
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improvement, as well as working data to obtain information to publish or to design clinical studies. 
Even though, I also like to perform QA activities because it allow to organise company’s work and , 
consequently, my work as well, in an efficient way, which is important to me because I challenge 
myself through organisation and perfection and because it is difficult for me to understand the lack 
of work coherence and linkage within a company. 
During the bachelor, master and extracurricular activities, I acquired extremely useful knowledge. 
Knowledge applicability covered all the tasks performed by me at DATAMEDICA, since budget 
proposals development to projects report. At the beginning of the internship, this was an individual 
motivation to perform the internship at a CRO and, nowadays, after ending my internship, I noticed 
that I was able to put into practice the knowledge acquired during my academic training and, when 
I had not learn the required information previously, I knew where to find it. The whole internship 
period had a learning component, which allowed me to increase my know-how and improve 
knowledge obtained at the university. Furthermore, I believe that the application of the theory is the 
better way to really understand it. 
The first months of the internship were very difficult, not only due to the reason of being a new 
experience, but I felt also that I was not given the necessary and adequate support to start my 
activities in DATAMEDICA’s. At first internship weeks, I thought that I would receive training in 
DATAMEDICA’s procedures, ICH GCP and European and national regulatory framework of Clinical 
Trials, which did not happen. Autonomously, I searched DATAMEDICA’s SOPs at office cabinets 
and files and I read SOPs that, as I found later, were not the updated documents. Also, the 
realisation of an activity that I never had performed before has seen as a terrifying situation 
because I did not felt the essential support of DATAMEDICA’s Scientific Management. At this time, 
all the support was given by my colleagues and I rarely received Managers’ feedback. However, 
due to human resources’ changes, this panorama improved and, nowadays DATAMEDICA’s 
employees work as a real team and the Manager’s feedback is given equally either to individual 
achievements or to the committed mistakes. Therefore, the idea of performing a new activity is less 
frightening and more stimulating because we know that there will be the necessary aid when we do 
not know what to do and that our work will be reviewed and corrected if necessary, as well as the 
reasons for modifications are going to be explained. 
Work in a CRO Full Service is a very demanding activity that requires good skills of 
communication, organization, attention, responsibility and mind flexibility. Communication is very 
important because a collaborator must know how to communicate with different professionals, such 
as Clients, health professionals, lay people or authorities’ representatives and, therefore, we must 
be able to adapt the speech according to the target audience, while keeping the scientific 
information/ message correct. This was not an easy task for me and, at the beginning of the 
internship, it required a great effort from me. Nowadays, I have notice that I have more capacity to 
communicate, which is related to the interaction with a diverse range of professionals, and, also, to 
work on my difficulties with the help from DATAMEDICA’s Managers. 
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My organization skills were improved due to the amount of projects, in which I was participating 
and, therefore, it was really important to have a methodical work and to keep a track of all the 
activities performed and to perform. Furthermore, the follow up of all DATAMEDICA’s project 
enhanced my mind flexibility because during work it was frequently required the ability to jump 
between projects and rapidly answer specific questions about the project’s status. Documents’ 
revision and monitoring activities, such as the preparation of visits, made me more focused in the 
details. Autonomously, I improved time management and proactivity skills in this 7-month 
experience. 
Besides time management, mind flexibility and organization, the amount of projects in which each 
collaborator was involved required a good activity planning, which is essential to prioritize tasks, 
activities and projects. Planning improves team efficiency, because it allows to save time, 
resources and energy and the team can be focused on urgent activities, and also assures 
alignment with the Clients and theirs requirements. However, planning should always be 
associated with flexibility and adaptability to new scenarios that require alteration to the prior plan. 
The internship allowed me to understand the interactivity between the different departments to 
deliver the services requested by Clients. It was possible to verify that all the inputs were valuable 
and, therefore, should always be shared and, even more, everyone can make the difference, so 
everyone is important. I become very quickly a valid and productive member of the team in behalf 
of my rapidly adaptation and desire to learn. I noticed this because other team members started 
requiring my opinion and feedback very soon. 
Multidisciplinary teams are difficult to manage, sometimes due to knowledge differences, others 
due to entropies related with personalities. Team building activities and transparent communication 
along with conflict management tools were important to diminish the occurrence of stressful 
situations between the team members and to allow the collaborators to grow as a team. 
Understandably, the lack of communication or mutual respect, poor planning, and lack of trust can 
result in undesirable outcomes that may have negative consequences over company’s services. 
Due to modifications of DATAMEDICA’s resources, some projects were faced with less knowledge. 
However, for all of them, it was possible to correctly respond to the arise difficulties and to 
overcome all the obstacles. These situations were also important on the development of my skills 
because they improved searching competences and critical thinking, simultaneously with the 
capacity of dealing with problems and promptly solve them. 
Repeated meetings with Clients are essential for the good conduction of the project. These 
meetings allow to understand the status of the project and to decide what to do next. However, I 
attended some unnecessary meetings, with the objective to perform Clients/ Investigators tasks 
instead of them. If DATAMEDICA’s collaborators have not schedule the meeting, Clients/ 
Investigators would not carry out their tasks, which would delay the project timelines. Furthermore, 
projects’ delays are seen by the Client has CRO’s low commitment and they do not understand the 
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involvement of external factors that delay the activities, such as submission and evaluation’s 
process, lack of answer by other involved parts or even lack of Client’s feedback. To avoid 
misinterpretations and conflicts, a good communication with the Client is necessary and, to protect 
CRO’s work, meetings and projects development should be always registered. During the 
internship, I developed the habit to write the summary of the meetings with the Client and delivery it 
to DATAMEDICA’s management. If they considered it necessary, this summary was sent to the 
Client. 
The interaction between CRO and Clients for potential future collaboration projects can be 
described as delicate at best. To maintenance old clients and acquisition of new ones is important 
to provide high-quality services at scheduled time. The satisfaction of a Client may bring new 
projects to DATAMEDICA. Also, a satisfied Client may reference DATAMEDICA to other 
companies as a good services’ provider. 
Regarding the activities performed in the scope of QA, I could realise that this is an enormous and 
very stimulating field. Maybe due to the enthusiasm of the QA Manager, I see a QMS has a “must 
have” for the correct and efficient work of a company. It maintains and improves efficiency in all the 
activities performed and it allows to implement tools that can identify gaps, flaws and possible 
processes that require improvement. Documentation of important information and document control 
are essential to avoid errors or forgetfulness of important tasks. Unfortunately, my participation in 
QA tasks was limited due to the necessity to develop other services and conduct other projects. I 
hope that in the future I may have other opportunities to work in QMS area and learn more about 
this area.  
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5. CONCLUSION 
To conclude this report, I would say that the opportunity to conduct my internship at 
DATAMEDICA’s was an important and enriching experience, considering all the activities 
performed and knowledge acquired. I was able to achieve all my objectives for the internship and 
play an active role in activities that can improve current clinical practice, such as Clinical Trials and 
advisory boards. 
I finish my second year of master with the feeling that I have accomplished the majority of my 
proposed goals defined at the beginning of this journey. This unique experience allowed me to 
grow and become a competent professional and I can say with great certain that this year was the 
most enriching one of my academic life. 
Every working day was full of new challenges and learning opportunities and we always made 
every efforts to end the day with the better quality service delivered to the Client. 
I cannot identify a major focus of the internship, which I do not see as a bad thing. The possibility to 
attend and conduct different activities increased my hard and soft skills exponentially. The 
knowledge acquired during the internship covers all the health products cycle of life and I feel 
capable to perform any Clinical Research-related activity. However, I know that skills and 
knowledge can always be improved. 
To sum this 7-month experience, the conduction of all the activities summarized in this report gave 
me all the background necessary to become a good professional in the clinical research area. I 
also understood that hard skills, such as writing, revision or statistical skills, can be learned and 
trained. For all competences, willingness to learn, repeated practice and experts’ support are 
essential tools to understand and apply during work all the specificities for each activity. 
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